{"gene":"CNR1","run_date":"2026-04-28T17:28:53","timeline":{"discoveries":[{"year":1990,"finding":"CB1 (CNR1) was cloned from rat brain cDNA and identified as a G protein-coupled receptor with seven transmembrane helices that inhibits adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner, establishing it as the neuronal receptor mediating cannabis effects.","method":"cDNA cloning, functional expression in cell lines, adenylate cyclase inhibition assay, radioligand binding","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original cloning with functional reconstitution; foundational paper with >3900 citations","pmids":["2165569"],"is_preprint":false},{"year":1991,"finding":"Human CB1 receptor cDNA was cloned from brain and testis; the protein shares 97.3% identity with rat CB1, and stably transfected CHO-K1 cells show dose-dependent, stereoselective inhibition of forskolin-induced cAMP accumulation upon cannabinoid agonist treatment, confirming functional coupling to Gi.","method":"cDNA cloning from human brain cDNA library, stable transfection in CHO-K1 cells, cAMP assay, radioligand binding ([3H]CP55940)","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in heterologous cells with functional readout; >535 citations","pmids":["1718258"],"is_preprint":false},{"year":1995,"finding":"Alternative splicing of the human CNR1 gene produces a shorter isoform (CB1A) lacking 61 N-terminal amino acids (with a distinct 28 amino acid N-terminus), present at up to 20% of CB1 levels in brain and peripheral tissues; a similar splice variant exists in rat.","method":"RT-PCR of human and rat cDNA libraries, cDNA sequencing, Northern blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct molecular characterization of splice variant with sequence verification; >247 citations","pmids":["7876112"],"is_preprint":false},{"year":1995,"finding":"CB1 receptor activation by the cannabinoid agonist CP-55940 in human astrocytoma cells (U373 MG) induces expression of the immediate-early gene krox-24 (egr-1/NGFI-A) via a pertussis toxin-sensitive G-protein pathway independent of cAMP metabolism; this was confirmed in CHO cells transfected with human CB1.","method":"Western blot, EMSA, pertussis toxin treatment, CHO cell transfection with human CB1, CB1 antagonist SR141716A blockade","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (Western blot, EMSA, pharmacological controls) with heterologous expression confirmation","pmids":["7775459"],"is_preprint":false},{"year":1999,"finding":"CB1 receptors undergo rapid agonist-induced internalization via clathrin-coated pits; internalization does not require activated Gαi, Gαo, or Gαs subunits; a region of the extreme C-terminus (last 14 residues) is necessary for internalization. Recycling of internalized CB1 to the cell surface requires endosomal acidification and dephosphorylation.","method":"Receptor internalization assays, hypertonic sucrose blockade, C-terminal truncation mutants, pharmacological tools in heterologous expression system","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 — systematic mutagenesis of internalization domain with multiple mechanistic controls; >243 citations","pmids":["10428044"],"is_preprint":false},{"year":1999,"finding":"GRK3 and β-arrestin 2 mediate homologous CB1 receptor desensitization in Xenopus oocytes; phosphorylation of S426 or S430 in the C-terminal tail is required for desensitization but not for internalization, establishing distinct molecular domains for these two regulatory processes.","method":"Xenopus oocyte electrophysiology (Kir3 current), co-expression of GRK3/β-arrestin 2, site-directed mutagenesis of S426A and S430A, CB1 C-terminal truncation mutants","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis defining specific phosphorylation sites; >209 citations","pmids":["10234009"],"is_preprint":false},{"year":2000,"finding":"CB1 receptor activation mediates cell migration (chemotaxis and chemokinesis) in HEK293 cells via pertussis toxin-sensitive Gi proteins; the migratory response requires MAPK activation but not adenylate cyclase inhibition.","method":"Boyden chamber migration assay with stable CB1-expressing HEK293 cells, pertussis toxin treatment, MEK inhibitor PD098059, CB1 antagonist SR141716A, checkerboard analysis","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 2 — heterologous expression with pharmacological controls and multiple mechanistic tests","pmids":["10871313"],"is_preprint":false},{"year":2005,"finding":"CB1 receptors are localized in lipid raft microdomains in C6 glioma cells; disruption of lipid rafts with methyl-β-cyclodextrin (MCD) approximately doubles CB1 binding efficiency and amplifies CB1-dependent signaling via adenylate cyclase and p42/p44 MAPK; CB1 activation within rafts underlies anandamide-induced apoptosis and cytochrome c release.","method":"Membrane fractionation, [35S]GTPγS binding assay, adenylate cyclase assay, MAPK phosphorylation, apoptosis assay (cytochrome c release), methyl-β-cyclodextrin disruption of rafts","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods linking lipid raft localization to CB1 functional signaling","pmids":["15657045"],"is_preprint":false},{"year":2005,"finding":"CB1 receptor activation by WIN55,212-2 increases intracellular calcium via coupling to Gq/11 proteins and phospholipase C, releasing calcium from IP3- and ryanodine receptor-sensitive intracellular stores; this Gq-mediated calcium mobilization is WIN-specific and not triggered by other cannabinoid agonist classes (THC, CP55940, anandamide, HU-210).","method":"Calcium photometry in CB1-expressing HEK293 cells and hippocampal neurons, pertussis toxin pretreatment, dominant-negative Gαq expression, PLC inhibitors, IP3 receptor and ryanodine receptor inhibitors","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with dominant-negative proteins, pharmacological dissection, and multiple inhibitors confirming the signaling pathway","pmids":["16365309"],"is_preprint":false},{"year":2004,"finding":"Human sperm express CB1 (but not CB2) receptor, localized to the sperm head and midpiece; CB1 activation by anandamide reduces sperm motility, inhibits capacitation-induced acrosome reaction, causes rapid plasma membrane hyperpolarization, and reduces mitochondrial activity, all reversed by CB1 antagonist SR141716A.","method":"RT-PCR, Western blot, anandamide treatment with CB1 antagonist, rhodamine 123 fluorescence (mitochondrial activity), intracellular calcium measurement, K+ channel blockade","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 — multiple functional readouts with receptor-specific pharmacological controls in native human tissue","pmids":["15562018"],"is_preprint":false},{"year":2007,"finding":"Striatal CB1 and adenosine A2A receptors form heteromeric complexes demonstrated in co-transfected HEK-293T cells and rat striatum; CB1 receptor signaling in a neuroblastoma cell line is completely dependent on A2A receptor activation, and intrastriatal A2A receptor blockade counteracts cannabinoid-induced motor depression.","method":"Co-immunoprecipitation, co-localization immunofluorescence in striatum, bimolecular fluorescence complementation, cAMP assays, in vivo intrastriatal pharmacology","journal":"Neuropsychopharmacology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal biochemical and functional evidence for heteromer formation with in vivo behavioral validation","pmids":["17356572"],"is_preprint":false},{"year":2009,"finding":"CB1 receptors promote oxidative stress and cardiomyocyte cell death via reactive oxygen species generation and activation of p38 and JNK MAPK pathways; CB1 knockout mice show markedly attenuated doxorubicin-induced cardiac dysfunction and cell death, and CB1 agonists (AEA, HU210) enhance doxorubicin-induced MAPK activation and cell death in human primary cardiomyocytes.","method":"CB1 knockout mice, pressure-volume conductance system (cardiac function), MAPK activation (Western blot), flow cytometry (ROS, cell death), co-administration of CB1 agonists/antagonists and MAPK inhibitors in human cardiomyocytes","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout plus pharmacological dissection in both mouse models and primary human cells","pmids":["19942623"],"is_preprint":false},{"year":2010,"finding":"CB1 and β2-adrenoceptors form physical heteromers (demonstrated by BRET) in HEK293H cells; co-expression reduces CB1 constitutive activity, increases CB1 cell surface expression, and alters signaling: enhancing Gαi-dependent ERK phosphorylation but decreasing non-Gαi-mediated CREB phosphorylation; similar functional interactions occur in primary human trabecular meshwork cells endogenously co-expressing both receptors.","method":"BRET, receptor trafficking assays, ERK phosphorylation, CREB phosphorylation, CB1 inverse agonist AM251 vs. neutral antagonist O-2050 pharmacology","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 — BRET heteromer detection plus multiple functional readouts validated in endogenous cell system","pmids":["20590567"],"is_preprint":false},{"year":2011,"finding":"CB1 receptor activation by AEA (but not 2-AG unless MAGL is inhibited) suppresses RhoA GTPase activity in prostate carcinoma cells, causing loss of actin/myosin microfilaments and reduced cell migration; CB1 antagonism (AM251) increases RhoA activity and promotes migration, indicating constitutive endocannabinoid-CB1 tone chronically represses RhoA.","method":"RhoA/Rac1/Cdc42 activity pull-down assays, CB1 agonist/antagonist treatment (WIN55212, AM251), MAGL inhibitor JZL184, actin/myosin staining, Boyden chamber migration assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — biochemical GTPase assays with pharmacological dissection linked to defined cellular phenotype","pmids":["22087025"],"is_preprint":false},{"year":2012,"finding":"CB1 and CB2 cannabinoid receptors form heteromers in transfected neuronal cells and in rat brain regions (pineal gland, nucleus accumbens, globus pallidus); within these heteromers, co-activation of CB1 and CB2 produces negative cross-talk in Akt phosphorylation and neurite outgrowth, and CB1 antagonists can block CB2 agonist effects and vice versa (bidirectional cross-antagonism).","method":"BRET, FRET, co-immunoprecipitation, neurite outgrowth assay, Akt phosphorylation, rat brain tissue biochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple biophysical methods demonstrating heteromer formation plus functional readouts; replicated in native tissue","pmids":["22532560"],"is_preprint":false},{"year":2012,"finding":"GPR55 and CB1 receptors form heteromers in HEK293 cells; co-expression of CB1 specifically inhibits GPR55-mediated transcription factor activation (NFAT, SRE) and ERK1/2 phosphorylation, while GPR55 presence enhances CB1-mediated ERK1/2 and NFAT activation; internalization of both receptors is unaffected by heteromerization.","method":"Co-immunoprecipitation, BRET, transcription factor activation assays (NFAT, SRE luciferase), ERK1/2 phosphorylation, receptor internalization assays in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — BRET plus multiple functional signaling readouts demonstrating heteromer-specific pharmacology","pmids":["23161546"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of human CB1 in complex with the antagonist AM6538 determined at 2.8 Å resolution, revealing the orthosteric binding pocket architecture and key residues for antagonist/agonist interactions; combined with molecular modeling, the structure explains binding modes of THC and synthetic cannabinoids.","method":"X-ray crystallography (2.8 Å), molecular modeling, functional studies","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with functional validation; >422 citations","pmids":["27768894"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of CB1 bound to the negative allosteric modulator (NAM) ORG27569 and agonist CP55940 reveals the NAM binds to an extrahelical site within the inner membrane leaflet overlapping a conserved cholesterol-binding site in class A GPCRs; the ternary complex captures an intermediate state where aromatic residues at the base of the agonist-binding pocket adopt an inactive conformation despite orthosteric pocket contraction.","method":"X-ray crystallography (ternary complex structure), mutagenesis, radioligand binding assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution structure with functional validation; >147 citations","pmids":["31659318"],"is_preprint":false},{"year":2022,"finding":"Cryo-EM and crystal structures of CB1 bound to positive allosteric modulator (PAM) ZCZ011 show it binds to an extrahelical TM2-TM3-TM4 site; molecular dynamics simulations and mutagenesis reveal TM2 rearrangement is critical for allosteric signal propagation — PAM ZCZ011 promotes TM2 rearrangement favoring receptor activation, while NAM ORG27569 (binding the same site) impedes TM2 rearrangement.","method":"X-ray crystallography, cryo-EM, molecular dynamics simulations, mutagenesis, functional assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 — multiple structural methods plus MD simulations and mutagenesis revealing the allosteric mechanism","pmids":["35637350"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of CB1 in active signaling complex with the endocannabinoid analog AMG315 (anandamide analog) reveals eCB-specific binding pocket features; ligand interactions with 'toggle switch' residues F200(3.36) and W356(6.48) and with TM2 drive intracellular TM2 rearrangements that determine G protein activation efficacy — these TM2 changes are unique to CB1 and are exploited by CB1-specific allosteric modulators.","method":"Cryo-EM, docking, molecular dynamics simulations, mutagenesis, Gα signaling assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM active-state structure with MD and mutagenesis mechanistic validation","pmids":["37160876"],"is_preprint":false},{"year":2008,"finding":"CB1 receptor is required for normal axonal growth and fasciculation during embryonic development; pharmacological inhibition of CB1 in chick embryos and morpholino-mediated knockdown in zebrafish both caused defects in axon pathfinding and fasciculation, coincident with expression of enzymes for 2-AG synthesis in overlapping patterns.","method":"CB1 pharmacological inhibition in chick embryo, morpholino knockdown in zebrafish, immunohistochemistry, in situ hybridization","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockdown plus pharmacological inhibition in two vertebrate models with defined developmental phenotype","pmids":["18378465"],"is_preprint":false},{"year":2008,"finding":"Loss of CB1 (Cnr1−/−) induces preterm birth in mice; CB1 deficiency alters progesterone/estrogen ratios prior to parturition and causes aberrant corticotropin-releasing hormone (CRH) and corticosterone secretion; CRH antagonist rescues normal parturition timing in Cnr1−/− mice, and excess corticosterone induces preterm birth in wild-type mice, placing CB1 upstream of the CRH-driven endocrine axis in labor regulation.","method":"Cnr1 knockout mice (genetic), radioimmunoassay of steroid hormones, CRH antagonist treatment, corticosterone administration in WT mice, Ptgs1/Cnr1 double-knockout epistasis","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with double KO and pharmacological rescue defining CB1's position in the parturition endocrine axis","pmids":["18833324"],"is_preprint":false},{"year":2006,"finding":"CB1 receptor antagonism (SR141716A) in mice and Cnr1−/− mice reduces liver fibrosis progression in three chronic liver injury models; CB1 activation by endocannabinoids promotes fibrogenesis by increasing hepatic TGF-β1 and by promoting survival and proliferation of hepatic myofibroblasts; CB1 is highly induced in human cirrhotic liver and in liver fibrogenic cells.","method":"Cnr1 knockout mice, CB1 antagonist SR141716A in three chronic liver injury models, TGF-β1 measurement, fibrogenic cell apoptosis/proliferation assays, human cirrhotic tissue immunohistochemistry","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout replicated by pharmacological antagonism in multiple disease models; >430 citations","pmids":["16715087"],"is_preprint":false},{"year":2011,"finding":"Genetic and siRNA-mediated inactivation of CB1 receptors inhibits bFGF-induced endothelial proliferation, migration, and tube formation through prosurvival/migratory pathways involving ERK, Akt, FAK, JNK, Rho, and MMP-2; CB1 blockade inhibits neovascular growth in rabbit cornea and reduces pathologic neovascularization in mouse oxygen-induced retinopathy in vivo.","method":"siRNA knockdown of CB1, CB1 antagonist pharmacology, endothelial proliferation/migration/tube formation assays, ERK/Akt/FAK/JNK/Rho/MMP-2 pathway analysis, rabbit cornea neovascularization assay, mouse oxygen-induced retinopathy model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic silencing plus pharmacological antagonism with defined signaling pathway readouts and in vivo validation","pmids":["21460248"],"is_preprint":false},{"year":2011,"finding":"CB1 receptor activity on hippocampal GABAergic (but not glutamatergic) neurons protects against age-dependent cognitive decline, pyramidal cell degeneration, and neuroinflammation; conditional deletion of CB1 from forebrain GABAergic neurons replicates the hippocampal neuron loss and elevated IL-6/microglial activation seen in complete Cnr1−/− mice.","method":"Conditional Cnr1 knockout (GABAergic vs. glutamatergic specific), Morris water maze, neuronal counting, IL-6 ELISA, immunohistochemistry for astrocytes and microglia","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional knockout with defined molecular and cellular phenotype","pmids":["21690345"],"is_preprint":false},{"year":2014,"finding":"CB1 receptors on glutamatergic (but not GABAergic) corticostriatal terminals are the essential population mediating neuroprotective effects of cannabinoids; conditional deletion of CB1 from glutamatergic neurons removes neuroprotection against quinolinic acid excitotoxicity and in the R6/2 Huntington disease model, while GABAergic CB1 deletion does not.","method":"Conditional Cnr1 knockout (glutamatergic vs. GABAergic), quinolinic acid excitotoxicity model, R6/2 Huntington mouse model, DREADD pharmacogenetic remote manipulation of corticostriatal projections","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional knockout with two disease models and orthogonal chemogenetic approach","pmids":["24843137"],"is_preprint":false},{"year":2013,"finding":"CB1 activation in neural stem cells (NSCs) via anandamide or ACEA (CB1-specific agonist but not CB2-specific agonist) enhances neuronal differentiation and maturation via long-term inhibition of the ERK1/2 pathway; pharmacological ERK1/2 inhibition mimics CB1-driven neuronal differentiation; CB1 activation also upregulates neuronal differentiation genes and suppresses stemness genes.","method":"NSC differentiation assays (ALP activity, morphometric neurite analysis), ERK1/2 phosphorylation assay, selective CB1/CB2 agonists and antagonists, gene array profiling, RT-PCR and Western blot","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — selective receptor pharmacology with multiple functional readouts and gene expression profiling","pmids":["23372698"],"is_preprint":false},{"year":2017,"finding":"CB1 receptor activation in human bone marrow MSCs enhances osteogenic differentiation by increasing mitochondrial energy metabolism (oxygen consumption rate, mitochondrial membrane potential) and Nrf1/Nrf2 expression; CB1 activates JNK and p38 MAPK pathways while inhibiting Erk1/2, and CB1 can rescue impaired osteogenic differentiation caused by mitochondrial electron transport chain inhibition.","method":"Alkaline phosphatase assay, alizarin red staining, Seahorse Mito Stress Test (OCR), JC-10 MMP assay, Western blot for signaling kinases, rotenone and CoQ10 pharmacology, CB1 siRNA knockdown","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mechanistic readouts in human primary cells with pharmacological and genetic perturbation","pmids":["35063024"],"is_preprint":false},{"year":2019,"finding":"Cannabinoids (Δ9-THC, HU-210, CP55940) inhibit Sonic Hedgehog signaling by blocking Smoothened (Smo) function; proximity ligation assays identified CB1-Smo heteromers in vivo, suggesting allosteric CB1-Smo interactions underlie CB-induced craniofacial and brain developmental defects in mice and zebrafish; a CB1 antagonist attenuated cannabinoid-induced birth defects.","method":"Mouse and zebrafish developmental models, Shh pathway reporter assays, proximity ligation assay (CB1-Smo heteromers), CB1 antagonist rescue experiments","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — proximity ligation evidence for novel CB1-Smo heteromers plus in vivo genetic/pharmacological rescue; single lab","pmids":["31690747"],"is_preprint":false},{"year":2017,"finding":"Cannabidiol-induced melanogenesis in human epidermal melanocytes is mediated by CB1 receptor (not CB2), acting through phosphorylation of p38 MAPK and p42/44 MAPK to upregulate MITF gene expression and downstream melanogenic enzymes (tyrosinase, TRP1, TRP2), independently of cAMP-PKA signaling.","method":"Melanin content assay, tyrosinase activity assay, CB1/CB2 selective antagonists, kinase inhibitors, RT-PCR and Western blot in human melanocytes","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 — selective receptor antagonism with multiple signaling readouts in human primary cells","pmids":["28601556"],"is_preprint":false},{"year":2008,"finding":"CB1 receptor constitutive activity maintains TRPV1 channels in a sensitized state responsive to capsaicin; CB1 knockout mice show markedly reduced capsaicin-evoked CGRP release from spinal cord and reduced action potential firing in isolated skin-nerve preparations, without differences in TRPV1 expression; CB1 inverse agonists inhibit capsaicin-induced calcium influx and nociceptive flinching.","method":"CB1 knockout mice, capsaicin-evoked CGRP release from spinal cord tissue, skin-nerve electrophysiology, calcium influx assay in F-11 cells, nociceptive behavioral tests, galanin/bradykinin sensitization rescue","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — genetic knockout with multiple mechanistic endpoints (neurochemical, electrophysiological, and behavioral) establishing constitutive CB1 activity as a prerequisite for TRPV1 sensitization","pmids":["18987195"],"is_preprint":false}],"current_model":"CNR1/CB1 is a seven-transmembrane Gi/o-coupled GPCR that inhibits adenylate cyclase, activates MAPK cascades, regulates voltage-gated Ca2+ and inwardly-rectifying K+ channels, and can also couple to Gq/11 to mobilize intracellular calcium; desensitization is mediated by GRK3 phosphorylation of S426/S430 and β-arrestin 2 recruitment, while distinct C-terminal residues govern clathrin-dependent internalization and recycling; structural studies have defined the orthosteric binding pocket and two extrahelical allosteric sites at the TM2-TM3-TM4 surface whose occupancy controls TM2 rearrangements that bias G protein coupling efficacy; CB1 forms functional heteromers with CB2, A2A, β2-adrenergic, GPR55, and Smoothened receptors that alter signaling properties; in vivo, cell-type-restricted CB1 populations (glutamatergic vs. GABAergic terminals) serve distinct physiological roles including neuroprotection, fear extinction, axonal development, parturition, liver fibrosis, angiogenesis, osteogenesis, sperm function, and intestinal permeability."},"narrative":{"teleology":[{"year":1990,"claim":"Cloning of CB1 from rat brain established it as the first molecularly identified cannabinoid receptor and demonstrated that it is a GPCR that inhibits adenylate cyclase via pertussis toxin-sensitive G proteins, answering the long-standing question of how cannabinoids signal in the CNS.","evidence":"cDNA cloning, functional expression in cell lines with adenylate cyclase assays and radioligand binding","pmids":["2165569"],"confidence":"High","gaps":["No structural information on the ligand-binding pocket","Downstream signaling beyond cAMP inhibition unknown","Endogenous ligand not yet identified at the time"]},{"year":1995,"claim":"Identification of an alternative splice variant (CB1A) and CB1-mediated immediate-early gene induction via a cAMP-independent pathway revealed that CB1 signaling extends beyond adenylate cyclase inhibition, opening the MAPK/transcriptional axis of cannabinoid signaling.","evidence":"RT-PCR/Northern blot for splice variants; Western blot and EMSA for krox-24 induction in astrocytoma cells with pertussis toxin sensitivity confirmed in CB1-transfected CHO cells","pmids":["7876112","7775459"],"confidence":"High","gaps":["Functional consequences of CB1A isoform unknown","Specific MAPK cascade components not yet mapped","In vivo relevance of cAMP-independent signaling not established"]},{"year":1999,"claim":"Mutagenesis of the CB1 C-terminal tail resolved the paradox of how desensitization and internalization can be independently regulated: GRK3/β-arrestin 2 act on S426/S430 for desensitization, while a distinct extreme C-terminal domain governs clathrin-dependent internalization and recycling.","evidence":"Xenopus oocyte electrophysiology with GRK3/β-arrestin 2 co-expression and S426A/S430A mutagenesis; receptor internalization assays with C-terminal truncation mutants and hypertonic sucrose blockade","pmids":["10234009","10428044"],"confidence":"High","gaps":["Phosphorylation sites for internalization not mapped","Endosomal sorting machinery not identified","In vivo desensitization kinetics unknown"]},{"year":2005,"claim":"Two studies expanded the signaling repertoire of CB1: lipid raft localization was shown to constrain CB1 signaling efficacy and enable raft-dependent apoptosis, while ligand-selective coupling to Gq/11 demonstrated that CB1 can mobilize intracellular calcium via PLC independently of Gi/o.","evidence":"Membrane fractionation and raft disruption with functional assays in C6 glioma; calcium photometry with dominant-negative Gαq, PLC/IP3R/RyR inhibitors in HEK293 and hippocampal neurons","pmids":["15657045","16365309"],"confidence":"High","gaps":["Structural basis for ligand-selective G protein coupling unknown","Physiological triggers for Gq vs. Gi coupling not defined","Lipid raft dynamics in native neurons not characterized"]},{"year":2006,"claim":"Demonstration that CB1 promotes liver fibrosis via TGF-β1 and hepatic myofibroblast survival, with Cnr1 knockout or antagonism reducing fibrosis in three injury models, established CB1 as a major peripheral signaling axis in chronic liver disease.","evidence":"Cnr1 knockout mice and pharmacological CB1 antagonism in three chronic liver injury models; TGF-β1 measurement; human cirrhotic tissue immunohistochemistry","pmids":["16715087"],"confidence":"High","gaps":["Direct CB1-expressing cell type in liver fibrosis pathway not conditionally targeted","Mechanism linking CB1 to TGF-β1 induction not resolved","Relevance to human fibrosis progression not tested prospectively"]},{"year":2008,"claim":"Three independent studies established diverse in vivo CB1 functions: constitutive CB1 activity tonically sensitizes TRPV1 nociceptive channels, CB1 is required for normal axonal growth and fasciculation during embryonic development, and CB1 deficiency causes preterm birth by deregulating the CRH-corticosterone endocrine axis.","evidence":"CB1 knockout mice with CGRP release and skin-nerve electrophysiology; morpholino knockdown in zebrafish plus chick embryo pharmacology; Cnr1 knockout mice with steroid hormone assays and CRH antagonist rescue","pmids":["18987195","18378465","18833324"],"confidence":"High","gaps":["Molecular mechanism by which constitutive CB1 activity sensitizes TRPV1 not identified","Endocannabinoid ligand identity for axon guidance not defined","Human relevance of CB1-CRH axis in parturition not established"]},{"year":2010,"claim":"Discovery of CB1–β2-adrenoceptor heteromers by BRET showed that receptor heterodimerization remodels CB1 constitutive activity, surface trafficking, and signaling bias, validated in primary human trabecular meshwork cells.","evidence":"BRET in HEK293H cells; ERK and CREB phosphorylation assays; confirmation in primary human cells endogenously co-expressing both receptors","pmids":["20590567"],"confidence":"High","gaps":["Stoichiometry and structure of the heteromer unknown","In vivo physiological consequences of CB1–β2AR heteromers not tested","Heteromer-selective pharmacology not developed"]},{"year":2012,"claim":"Identification of CB1–CB2 and CB1–GPR55 heteromers with distinct cross-talk properties (bidirectional cross-antagonism for CB1–CB2; asymmetric ERK/NFAT modulation for CB1–GPR55) demonstrated that heteromerization is a general mechanism diversifying cannabinoid receptor pharmacology.","evidence":"BRET, FRET, co-immunoprecipitation, neurite outgrowth and Akt/ERK assays in neuronal cells and rat brain tissue (CB1–CB2); BRET and transcription factor reporters in HEK293 (CB1–GPR55)","pmids":["22532560","23161546"],"confidence":"High","gaps":["Native tissue stoichiometry and heteromer prevalence not quantified","Downstream effectors unique to heteromers vs. homomers not mapped","Therapeutic targeting of specific heteromers not achieved"]},{"year":2014,"claim":"Cell-type-specific conditional knockouts resolved a key question: CB1 on glutamatergic terminals mediates neuroprotection against excitotoxicity (including in Huntington models), while CB1 on GABAergic neurons prevents age-related hippocampal neurodegeneration and neuroinflammation—establishing that a single receptor exerts opposing circuit-level effects depending on cell type.","evidence":"Conditional Cnr1 knockout from glutamatergic vs. GABAergic neurons; quinolinic acid excitotoxicity and R6/2 Huntington models; Morris water maze; IL-6 and microglia immunohistochemistry","pmids":["24843137","21690345"],"confidence":"High","gaps":["Intracellular signaling cascades in each cell type not compared","Whether circuit-level effects are purely presynaptic not resolved","Translation to human neurodegenerative disease not demonstrated"]},{"year":2016,"claim":"The first crystal structure of CB1 (with antagonist AM6538 at 2.8 Å) revealed the orthosteric binding pocket architecture and key ligand-contact residues, enabling rational interpretation of cannabinoid structure–activity relationships.","evidence":"X-ray crystallography at 2.8 Å resolution with molecular modeling and functional validation","pmids":["27768894"],"confidence":"High","gaps":["Active-state structure not yet available at this point","Allosteric sites not structurally resolved","Membrane environment effects not captured in crystal"]},{"year":2019,"claim":"Crystal structure of the CB1–ORG27569–CP55940 ternary complex identified an extrahelical NAM site in the inner membrane leaflet overlapping a cholesterol-binding site, capturing an intermediate conformational state that explained how allosteric modulators decouple agonist binding from receptor activation.","evidence":"X-ray crystallography of ternary complex; mutagenesis; radioligand binding assays","pmids":["31659318"],"confidence":"High","gaps":["Dynamic transitions between intermediate and active states not resolved","In vivo relevance of NAM-stabilized intermediate unknown","Selectivity determinants over CB2 at allosteric site not fully mapped"]},{"year":2022,"claim":"Structures of CB1 with PAM ZCZ011 at the same TM2-TM3-TM4 extrahelical site as the NAM, combined with MD simulations, revealed that PAM and NAM oppositely control TM2 rearrangement—the key conformational switch determining G protein coupling efficacy—providing a unified allosteric mechanism.","evidence":"X-ray crystallography and cryo-EM; molecular dynamics simulations; mutagenesis; functional assays","pmids":["35637350"],"confidence":"High","gaps":["Whether TM2 rearrangement controls β-arrestin bias not determined","Allosteric cooperativity with orthosteric agonists quantified only for select ligands","Endogenous allosteric modulators of this site not identified"]},{"year":2023,"claim":"Active-state cryo-EM structure with an endocannabinoid analog showed that eCB-specific contacts with toggle-switch residues F200/W356 and TM2 drive the G protein activation-determining TM2 rearrangement unique to CB1, explaining how endocannabinoids exploit a receptor-specific activation mechanism.","evidence":"Cryo-EM of active CB1-Gi complex; docking; MD simulations; mutagenesis and Gα signaling assays","pmids":["37160876"],"confidence":"High","gaps":["Full signaling complex including β-arrestin not yet structurally resolved","How distinct endocannabinoids (AEA vs. 2-AG) produce differential TM2 conformations is unclear","Integration of allosteric and orthosteric structural data into predictive pharmacology models incomplete"]},{"year":null,"claim":"Key open questions include: how CB1 heteromer stoichiometry and tissue-specific assembly determine pharmacological outcomes in vivo; the structural basis for ligand-biased Gi vs. Gq coupling; whether endogenous allosteric modulators of the TM2-TM3-TM4 site exist; and how cell-type-specific CB1 signaling cascades produce opposing circuit-level phenotypes in the CNS.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Heteromer-selective therapeutics not developed","Endogenous allosteric modulators unknown","β-arrestin-biased structural states not captured"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,8,16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,30]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,4,7,9]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,3,6,8,11,13,26,29]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[5,10,24,25,30]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[20,21,28]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[9,21]}],"complexes":[],"partners":["ARRB2","GRK3","ADORA2A","ADRB2","CNR2","GPR55","SMO","TRPV1"],"other_free_text":[]},"mechanistic_narrative":"CNR1 (CB1) is a Gi/o-coupled seven-transmembrane receptor that serves as the principal neuronal mediator of endocannabinoid signaling, with additional critical roles in peripheral tissues including liver, vasculature, bone, reproductive organs, and skin. CB1 inhibits adenylate cyclase and activates MAPK cascades (ERK1/2, p38, JNK) through pertussis toxin-sensitive G proteins, and can additionally couple to Gq/11 in a ligand-selective manner to mobilize intracellular calcium via PLC and IP3/ryanodine receptor stores [PMID:2165569, PMID:16365309, PMID:10871313]. Desensitization requires GRK3-mediated phosphorylation of C-terminal residues S426/S430 and β-arrestin 2 recruitment, while clathrin-dependent internalization depends on a distinct extreme C-terminal domain [PMID:10234009, PMID:10428044]; structural studies have defined the orthosteric binding pocket and an extrahelical TM2-TM3-TM4 allosteric site where positive and negative modulators control TM2 rearrangements that determine G protein coupling efficacy [PMID:27768894, PMID:31659318, PMID:35637350]. Cell-type-restricted CB1 populations exert distinct physiological functions—CB1 on glutamatergic terminals mediates neuroprotection against excitotoxicity, whereas CB1 on GABAergic neurons protects against age-dependent neurodegeneration and neuroinflammation—and CB1 forms functional heteromers with A2A, β2-adrenergic, CB2, GPR55, and Smoothened receptors that reshape downstream signaling [PMID:24843137, PMID:21690345, PMID:17356572, PMID:20590567, PMID:22532560, PMID:23161546]."},"prefetch_data":{"uniprot":{"accession":"P21554","full_name":"Cannabinoid receptor 1","aliases":["CANN6"],"length_aa":472,"mass_kda":52.9,"function":"G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727, PubMed:35637350). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells (PubMed:23955712) Binds both 2-arachidonoylglycerol (2-AG) and anandamide Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 2 in assays measuring GTP binding to membranes Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 3 in assays measuring GTP binding to membranes","subcellular_location":"Cell membrane; Membrane raft; Mitochondrion outer membrane; Cell projection, axon; Presynapse","url":"https://www.uniprot.org/uniprotkb/P21554/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CNR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CNR1","total_profiled":1310},"omim":[{"mim_id":"618538","title":"CANNABINOID RECEPTOR-INTERACTING PROTEIN 1; CNRIP1","url":"https://www.omim.org/entry/618538"},{"mim_id":"615687","title":"BECLIN 2; BECN2","url":"https://www.omim.org/entry/615687"},{"mim_id":"615353","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 28A; CCDC28A","url":"https://www.omim.org/entry/615353"},{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"609699","title":"MONOGLYCERIDE LIPASE; MGLL","url":"https://www.omim.org/entry/609699"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Actin filaments","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":18.3},{"tissue":"brain","ntpm":18.6}],"url":"https://www.proteinatlas.org/search/CNR1"},"hgnc":{"alias_symbol":["CB1K5","CB-R","CB1","CANN6","CB1A"],"prev_symbol":["CNR"]},"alphafold":{"accession":"P21554","domains":[{"cath_id":"1.20.1070.10","chopping":"105-312_334-411","consensus_level":"medium","plddt":91.2647,"start":105,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21554","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21554-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21554-F1-predicted_aligned_error_v6.png","plddt_mean":71.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CNR1","jax_strain_url":"https://www.jax.org/strain/search?query=CNR1"},"sequence":{"accession":"P21554","fasta_url":"https://rest.uniprot.org/uniprotkb/P21554.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21554/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21554"}},"corpus_meta":[{"pmid":"9336020","id":"PMC_9336020","title":"Pharmacology of cannabinoid CB1 and CB2 receptors.","date":"1997","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9336020","citation_count":1197,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15670612","id":"PMC_15670612","title":"Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15670612","citation_count":357,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19620237","id":"PMC_19620237","title":"Signal transduction of the CB1 cannabinoid receptor.","date":"2009","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19620237","citation_count":259,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28826534","id":"PMC_28826534","title":"CB1 and CB2 Receptor Pharmacology.","date":"2017","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28826534","citation_count":254,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10428044","id":"PMC_10428044","title":"Internalization and recycling of the CB1 cannabinoid receptor.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428044","citation_count":243,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20166926","id":"PMC_20166926","title":"CB(1) cannabinoid receptors and their associated proteins.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166926","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10234009","id":"PMC_10234009","title":"Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10234009","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15252281","id":"PMC_15252281","title":"CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.","date":"2004","source":"Behavioural pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15252281","citation_count":202,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22532560","id":"PMC_22532560","title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22532560","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11606489","id":"PMC_11606489","title":"Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.","date":"2001","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/11606489","citation_count":180,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16793875","id":"PMC_16793875","title":"Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes.","date":"2006","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16793875","citation_count":170,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12082570","id":"PMC_12082570","title":"CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12082570","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7775459","id":"PMC_7775459","title":"Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7775459","citation_count":148,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31659318","id":"PMC_31659318","title":"Structure of an allosteric modulator bound to the CB1 cannabinoid receptor.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31659318","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9106242","id":"PMC_9106242","title":"Cannabinoid receptor gene (CNR1): association with i.v. drug use.","date":"1997","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9106242","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24843137","id":"PMC_24843137","title":"A restricted population of CB1 cannabinoid receptors with neuroprotective activity.","date":"2014","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24843137","citation_count":131,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20381618","id":"PMC_20381618","title":"Depression-like phenotype following chronic CB1 receptor antagonism.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20381618","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18378465","id":"PMC_18378465","title":"The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation.","date":"2008","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18378465","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16527424","id":"PMC_16527424","title":"The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus.","date":"2006","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16527424","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21690345","id":"PMC_21690345","title":"Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21690345","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24882055","id":"PMC_24882055","title":"Stress regulates endocannabinoid-CB1 receptor signaling.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24882055","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20010552","id":"PMC_20010552","title":"Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.","date":"2009","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20010552","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18406468","id":"PMC_18406468","title":"Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!","date":"2008","source":"Journal of neuroscience methods","url":"https://pubmed.ncbi.nlm.nih.gov/18406468","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16570100","id":"PMC_16570100","title":"Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength.","date":"2006","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/16570100","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16623851","id":"PMC_16623851","title":"Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces.","date":"2006","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16623851","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15668727","id":"PMC_15668727","title":"Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).","date":"2005","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/15668727","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31690747","id":"PMC_31690747","title":"Cannabinoids Exacerbate Alcohol Teratogenesis by a CB1-Hedgehog Interaction.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31690747","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17018694","id":"PMC_17018694","title":"Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.","date":"2006","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17018694","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15755787","id":"PMC_15755787","title":"Rimonabant--a selective CB1 antagonist.","date":"2005","source":"The Annals of pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/15755787","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18279497","id":"PMC_18279497","title":"Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.","date":"2008","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/18279497","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23902803","id":"PMC_23902803","title":"Peripherally restricted CB1 receptor blockers.","date":"2013","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/23902803","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23161546","id":"PMC_23161546","title":"The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23161546","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34500853","id":"PMC_34500853","title":"CB1 Cannabinoid Receptor Signaling and Biased Signaling.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34500853","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18987195","id":"PMC_18987195","title":"Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18987195","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18482432","id":"PMC_18482432","title":"The role of CB1 receptors in psychostimulant addiction.","date":"2008","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/18482432","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27879006","id":"PMC_27879006","title":"Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.","date":"2016","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27879006","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35637350","id":"PMC_35637350","title":"Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35637350","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23108542","id":"PMC_23108542","title":"Endocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development.","date":"2012","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23108542","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11803524","id":"PMC_11803524","title":"Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1.","date":"2001","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11803524","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23372698","id":"PMC_23372698","title":"Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23372698","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23261520","id":"PMC_23261520","title":"The role of CB1 in immune modulation by cannabinoids.","date":"2012","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23261520","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21460248","id":"PMC_21460248","title":"Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21460248","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23647582","id":"PMC_23647582","title":"CB1 receptor signaling regulates social anxiety and memory.","date":"2013","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/23647582","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20590567","id":"PMC_20590567","title":"Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20590567","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25967266","id":"PMC_25967266","title":"Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25967266","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18851692","id":"PMC_18851692","title":"The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets.","date":"2008","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/18851692","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28334603","id":"PMC_28334603","title":"The CB1 Receptor as the Cornerstone of Exostasis.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28334603","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31013934","id":"PMC_31013934","title":"Structural Insights into CB1 Receptor Biased Signaling.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013934","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19093002","id":"PMC_19093002","title":"CB1 expression is attenuated in Fallopian tube and decidua of women with ectopic pregnancy.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19093002","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19725030","id":"PMC_19725030","title":"Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19725030","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28527758","id":"PMC_28527758","title":"Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.","date":"2017","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28527758","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16788767","id":"PMC_16788767","title":"(AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.","date":"2006","source":"European archives of psychiatry and clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16788767","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24836296","id":"PMC_24836296","title":"Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.","date":"2014","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24836296","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20192949","id":"PMC_20192949","title":"CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis.","date":"2011","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/20192949","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10462060","id":"PMC_10462060","title":"Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors.","date":"1999","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10462060","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9974174","id":"PMC_9974174","title":"The CB1 cannabinoid receptor in the brain.","date":"1998","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/9974174","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20218784","id":"PMC_20218784","title":"Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.","date":"2010","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20218784","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28700706","id":"PMC_28700706","title":"Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28700706","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27023732","id":"PMC_27023732","title":"Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?","date":"2016","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27023732","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28404744","id":"PMC_28404744","title":"The role of CB1 in intestinal permeability and inflammation.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28404744","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17669634","id":"PMC_17669634","title":"The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.","date":"2007","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17669634","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18833324","id":"PMC_18833324","title":"Loss of cannabinoid receptor CB1 induces preterm birth.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18833324","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15308578","id":"PMC_15308578","title":"Efficacy in CB1 receptor-mediated signal transduction.","date":"2004","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15308578","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16741937","id":"PMC_16741937","title":"Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16741937","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17873324","id":"PMC_17873324","title":"The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men.","date":"2007","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/17873324","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18468662","id":"PMC_18468662","title":"Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder.","date":"2008","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/18468662","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28601556","id":"PMC_28601556","title":"Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK.","date":"2017","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/28601556","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15542757","id":"PMC_15542757","title":"Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15542757","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10871313","id":"PMC_10871313","title":"CB1 cannabinoid receptor-mediated cell migration.","date":"2000","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/10871313","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37160876","id":"PMC_37160876","title":"Structural basis for activation of CB1 by an endocannabinoid analog.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37160876","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17881126","id":"PMC_17881126","title":"No association of CNR1 gene variations with susceptibility to schizophrenia.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17881126","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21714860","id":"PMC_21714860","title":"Variation in the human cannabinoid receptor CNR1 gene modulates gaze duration for happy faces.","date":"2011","source":"Molecular autism","url":"https://pubmed.ncbi.nlm.nih.gov/21714860","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17931621","id":"PMC_17931621","title":"The cannabinoid CB1 receptor is expressed on serotonergic and dopaminergic neurons.","date":"2007","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17931621","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17702901","id":"PMC_17702901","title":"Expression of cannabinoid CB1 receptors in models of diabetic neuropathy.","date":"2007","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17702901","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18505678","id":"PMC_18505678","title":"The cannabinoid CB1 receptor is expressed in pancreatic delta-cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18505678","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19075713","id":"PMC_19075713","title":"Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.","date":"2008","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/19075713","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29058339","id":"PMC_29058339","title":"Linking Mitochondria and Synaptic Transmission: The CB1 Receptor.","date":"2017","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29058339","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28752643","id":"PMC_28752643","title":"Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28752643","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26684509","id":"PMC_26684509","title":"Sex-dependence of anxiety-like behavior in cannabinoid receptor 1 (Cnr1) knockout mice.","date":"2015","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26684509","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31968549","id":"PMC_31968549","title":"Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31968549","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16169563","id":"PMC_16169563","title":"Development and expression of neuropathic pain in CB1 knockout mice.","date":"2005","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16169563","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16190768","id":"PMC_16190768","title":"High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor.","date":"2005","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16190768","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19165169","id":"PMC_19165169","title":"Variants in the CNR1 and the FAAH genes and adiposity traits in the community.","date":"2009","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19165169","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22087025","id":"PMC_22087025","title":"Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22087025","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21790903","id":"PMC_21790903","title":"Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis.","date":"2011","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/21790903","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35063024","id":"PMC_35063024","title":"The cannabinoid receptor I (CB1) enhanced the osteogenic differentiation of BMSCs by rescue impaired mitochondrial metabolism function under inflammatory condition.","date":"2022","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35063024","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20854251","id":"PMC_20854251","title":"Human platelets express authentic CB₁ and CB₂ receptors.","date":"2010","source":"Current neurovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20854251","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26370914","id":"PMC_26370914","title":"Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors.","date":"2015","source":"Epilepsy research","url":"https://pubmed.ncbi.nlm.nih.gov/26370914","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24950219","id":"PMC_24950219","title":"Cardiorespiratory anomalies in mice lacking CB1 cannabinoid receptors.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24950219","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31725603","id":"PMC_31725603","title":"The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31725603","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11341859","id":"PMC_11341859","title":"The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users.","date":"2001","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/11341859","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22850347","id":"PMC_22850347","title":"MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.","date":"2012","source":"Psychological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22850347","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26739712","id":"PMC_26739712","title":"Physiological impact of CB1 receptor expression by hippocampal GABAergic interneurons.","date":"2016","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26739712","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20370713","id":"PMC_20370713","title":"Understanding functional residues of the cannabinoid CB1.","date":"2010","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20370713","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18563799","id":"PMC_18563799","title":"Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.","date":"2008","source":"Chemical record (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18563799","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23621789","id":"PMC_23621789","title":"Novel adamantyl cannabinoids as CB1 receptor probes.","date":"2013","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23621789","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27500453","id":"PMC_27500453","title":"Lifetime use of cannabis from longitudinal assessments, cannabinoid receptor (CNR1) variation, and reduced volume of the right anterior cingulate.","date":"2016","source":"Psychiatry research. Neuroimaging","url":"https://pubmed.ncbi.nlm.nih.gov/27500453","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24175626","id":"PMC_24175626","title":"Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.","date":"2013","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/24175626","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27375550","id":"PMC_27375550","title":"Effects of Neuroendocrine CB1 Activity on Adult Leydig Cells.","date":"2016","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27375550","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27613640","id":"PMC_27613640","title":"Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system.","date":"2016","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/27613640","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2165569","id":"PMC_2165569","title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA.","date":"1990","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2165569","citation_count":3947,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11214319","id":"PMC_11214319","title":"Molecular phylogenetics and the origins of placental mammals.","date":"2001","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11214319","citation_count":862,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12060783","id":"PMC_12060783","title":"An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12060783","citation_count":692,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15728830","id":"PMC_15728830","title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.","date":"2005","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15728830","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1718258","id":"PMC_1718258","title":"Molecular cloning of a human cannabinoid receptor which is also expressed in testis.","date":"1991","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1718258","citation_count":535,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16715087","id":"PMC_16715087","title":"CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.","date":"2006","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16715087","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17065342","id":"PMC_17065342","title":"Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17065342","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27768894","id":"PMC_27768894","title":"Crystal Structure of the Human Cannabinoid Receptor CB1.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/27768894","citation_count":422,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11894096","id":"PMC_11894096","title":"The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11894096","citation_count":371,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12511587","id":"PMC_12511587","title":"Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/12511587","citation_count":311,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16365309","id":"PMC_16365309","title":"The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16365309","citation_count":266,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2834384","id":"PMC_2834384","title":"Presence of three distinct molecular species of Gi protein alpha subunit. Structure of rat cDNAs and human genomic DNAs.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2834384","citation_count":256,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7876112","id":"PMC_7876112","title":"An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7876112","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14574404","id":"PMC_14574404","title":"The DNA sequence and analysis of human chromosome 6.","date":"2003","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/14574404","citation_count":242,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15927811","id":"PMC_15927811","title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.","date":"2005","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/15927811","citation_count":239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19598235","id":"PMC_19598235","title":"Genes related to sex steroids, neural growth, and social-emotional behavior are associated with autistic traits, empathy, and Asperger syndrome.","date":"2009","source":"Autism research : official journal of the International Society for Autism Research","url":"https://pubmed.ncbi.nlm.nih.gov/19598235","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19596672","id":"PMC_19596672","title":"CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19596672","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17356572","id":"PMC_17356572","title":"Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids.","date":"2007","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17356572","citation_count":200,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15289816","id":"PMC_15289816","title":"Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse.","date":"2004","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/15289816","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18354002","id":"PMC_18354002","title":"Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18354002","citation_count":192,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15562018","id":"PMC_15562018","title":"Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15562018","citation_count":187,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12752773","id":"PMC_12752773","title":"Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain.","date":"2003","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12752773","citation_count":183,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18606950","id":"PMC_18606950","title":"Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia.","date":"2008","source":"Archives of general psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18606950","citation_count":182,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15657045","id":"PMC_15657045","title":"Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15657045","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19942623","id":"PMC_19942623","title":"CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/19942623","citation_count":178,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45979,"output_tokens":6442,"usd":0.117283},"stage2":{"model":"claude-opus-4-6","input_tokens":10072,"output_tokens":3525,"usd":0.207728},"total_usd":0.713047,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":60821,"output_tokens":7964,"usd":0.150961},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11985,"output_tokens":3925,"usd":0.237075}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CB1 receptor is a G protein-coupled receptor that couples to Gi/o proteins to inhibit adenylyl cyclase and regulate calcium and potassium ion channels, mediating cannabinoid effects in the central nervous system and peripheral tissues.\",\n      \"method\": \"Pharmacological characterization, in vitro binding and effector assays\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — replicated across multiple labs with multiple orthogonal methods; foundational pharmacological characterization\",\n      \"pmids\": [\"9336020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CB1 receptor activation by cannabinoid agonist CP-55940 induces expression of the immediate-early gene krox-24 (egr-1/NGFI-A) via a pertussis toxin-sensitive Gi/o protein pathway, independent of cAMP metabolism, in astrocytoma cells.\",\n      \"method\": \"Western blot, EMSA, pertussis toxin inhibition, CHO cells transfected with human CB1, CB1-selective antagonist SR141716A\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (Western blot, EMSA, pharmacological and genetic validation in transfected cells), replicated with receptor-specific antagonist\",\n      \"pmids\": [\"7775459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CB1 receptors undergo rapid agonist-induced internalization via clathrin-coated pits; the extreme carboxy terminus (last 14 residues) is necessary for internalization, and recycling of sequestered receptor requires endosomal acidification and dephosphorylation.\",\n      \"method\": \"Cell-based internalization assays, hypertonic sucrose inhibition, C-terminal deletion mutants, pharmacological intervention\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants and pharmacological tools with defined mechanistic readouts in a single rigorous study\",\n      \"pmids\": [\"10428044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CB1 receptor desensitization is mediated by GRK3 and beta-arrestin 2; phosphorylation of residues S426 and S430 in the C-terminal tail (residues 418-439) is required for GRK3/beta-arrestin 2-dependent desensitization, while internalization proceeds independently of these phosphorylation sites.\",\n      \"method\": \"Xenopus oocyte expression, Kir3 channel electrophysiology, GRK3/beta-arrestin 2 co-expression, CB1 C-terminal truncation and point mutants (S426A, S430A), AtT20 stable expression\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro reconstitution in oocytes with mutagenesis and multiple deletion constructs; distinct domains for desensitization vs internalization established\",\n      \"pmids\": [\"10234009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CB1 receptor activation by cannabinoid agonists induces cell migration (chemotaxis and chemokinesis) via Gi-protein-dependent activation of MAPK, independent of adenylyl cyclase inhibition.\",\n      \"method\": \"Modified Boyden chamber assay, pertussis toxin inhibition, PD098059 (MEK inhibitor), SR141716A antagonism, HEK293 cells stably transfected with human CB1\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean reconstituted system with pharmacological dissection of signaling pathway using multiple inhibitors and antagonists\",\n      \"pmids\": [\"10871313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB1 receptor signals predominantly through Gi/o proteins to inhibit adenylyl cyclase and regulate ion channels; it also activates MAPK pathways (ERK1/2, p38, JNK), stimulates phospholipases, and interacts with beta-arrestins to form signaling complexes; CB1 can form homo- and heterodimers/oligomers with altered pharmacological properties.\",\n      \"method\": \"Multiple signaling assays, co-immunoprecipitation, BRET/FRET for oligomerization, pharmacological characterization\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — comprehensive review of replicated findings across multiple labs and methods\",\n      \"pmids\": [\"19620237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CB1 receptor physically interacts with beta2-adrenoceptors (detected by BRET); co-expression increases CB1 cell surface expression, reduces its constitutive activity, increases Galphai-dependent ERK phosphorylation, and decreases non-Galphai-mediated CREB phosphorylation.\",\n      \"method\": \"BRET, receptor trafficking assays, ERK and CREB phosphorylation assays in HEK293H cells and primary human trabecular meshwork cells\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal biophysical and functional assays in heterologous and endogenous expression systems\",\n      \"pmids\": [\"20590567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB1 receptor forms heteromers with CB2 receptor in transfected neuronal cells and in rat brain (pineal gland, nucleus accumbens, globus pallidus); within CB1-CB2 heteromers, co-activation produces negative cross-talk in Akt phosphorylation and neurite outgrowth, and CB1 antagonists can block CB2 agonist effects (bidirectional cross-antagonism).\",\n      \"method\": \"Biophysical (BRET/FRET), biochemical (co-IP), functional signaling assays, rat brain tissue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biophysical and biochemical methods with functional validation in native tissue\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB1 receptor co-expressed with GPR55 forms heteromers; CB1 co-expression specifically inhibits GPR55-mediated transcription factor (NFAT, SRE) and ERK1/2 activation, while GPR55 enhances CB1-mediated ERK1/2 and NFAT activation, without affecting internalization of either receptor.\",\n      \"method\": \"Co-immunoprecipitation, signaling assays (NFAT, SRE reporter, ERK phosphorylation) in HEK293 cells stably expressing HA-GPR55 with FLAG-CB1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — single lab, multiple signaling readouts, heterologous expression system only\",\n      \"pmids\": [\"23161546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of CB1 bound to the negative allosteric modulator ORG27569 and agonist CP55940 reveals that NAM binds an extrahelical site in the inner leaflet of the membrane overlapping with a conserved cholesterol-interaction site; the ternary structure captures an intermediate receptor state with inactive aromatic residues at the base of the agonist-binding pocket despite orthosteric pocket contraction.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional validation\",\n      \"pmids\": [\"31659318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Crystal and cryo-EM structures of CB1 bound to positive allosteric modulator ZCZ011 show it binds an extrahelical TM2-TM3-TM4 site; MD simulations and mutagenesis demonstrate TM2 rearrangement is critical for allosteric signal propagation. ZCZ011 promotes TM2 rearrangement toward active conformation (PAM effect), while NAM ORG27569 binds same site and impedes TM2 rearrangement.\",\n      \"method\": \"X-ray crystallography, cryo-EM, molecular dynamics simulations, mutagenesis, functional assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods combined with MD simulations and mutagenesis in a single study\",\n      \"pmids\": [\"35637350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of CB1 in complex with endocannabinoid analog AMG315 reveals ligand-binding pocket details; MD simulations and mutagenesis show that interactions with 'toggle switch' residues F200(3.36) and W356(6.48) and ligand-TM2 interactions drive intracellular TM2 rearrangements unique to CB1 that are a determinant of G protein activation efficacy.\",\n      \"method\": \"Cryo-EM structure determination, docking, molecular dynamics simulations, mutagenesis, signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure plus simulation plus mutagenesis plus functional assays in single study\",\n      \"pmids\": [\"37160876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor is functionally present within brain mitochondria (mtCB1); acute activation of mtCB1 alters mitochondrial ATP generation, which modulates synaptic transmission and memory performance.\",\n      \"method\": \"Subcellular fractionation, functional mitochondrial assays, electrophysiology, behavioral testing\",\n      \"journal\": \"BioEssays\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — review citing original experimental findings on mtCB1; direct experimental evidence cited from multiple studies but this paper itself is a review\",\n      \"pmids\": [\"29058339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor activation inhibits RhoA GTPase activity in prostate carcinoma cells; this reduces actin/myosin microfilament formation, cell spreading, and migration. Endogenously produced endocannabinoids tonically activate CB1 to suppress RhoA and cell migration in an autocrine fashion.\",\n      \"method\": \"RhoA/Rac1/Cdc42 pull-down activity assays, phalloidin staining of actin, Boyden chamber migration assay, CB1 agonists/antagonists, MAGL inhibitor (JZL184), PC-3 cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking CB1 activation to RhoA inhibition and functional cell migration readout\",\n      \"pmids\": [\"22087025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CB1 receptor mediates the anti-emetic action of cannabinoids in the dorsal vagal complex of the brainstem; CB1 is localized in the area postrema, nucleus of the solitary tract, dorsal motor nucleus of the vagus, and myenteric plexus of the stomach and duodenum.\",\n      \"method\": \"Immunohistochemistry, pharmacological agonist/antagonist experiments in ferret emesis model\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — localization combined with pharmacological loss-of-function (antagonist reversal) establishing anti-emetic mechanism at defined brain region\",\n      \"pmids\": [\"11606489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB1 receptor mediates cannabinoid-induced suppression of glutamatergic synaptic transmission at Schaffer collateral/commissural fiber-CA1 pyramidal cell synapses in the hippocampus, as demonstrated in two independent CB1 knockout mouse lines.\",\n      \"method\": \"Extracellular field recordings in hippocampal slices, CB1 knockout mice (two independent lines), cannabinoid agonist WIN 55,212-2\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function confirmed in two independent knockout lines with electrophysiological readout\",\n      \"pmids\": [\"16527424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor function is required for normal axonal growth and fasciculation during early neuronal development; pharmacological CB1 inhibition and morpholino knockdown in zebrafish both cause defects in axon pathfinding and fasciculation.\",\n      \"method\": \"Pharmacological inhibition, zebrafish morpholino knockdown, developmental imaging\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with defined morphological phenotype in two experimental systems\",\n      \"pmids\": [\"18378465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor signaling on hippocampal GABAergic (but not glutamatergic) neurons protects against age-dependent cognitive decline by reducing pyramidal cell degeneration and neuroinflammation (increased IL-6, astrocytes, activated microglia), as shown by cell-type-specific conditional knockout.\",\n      \"method\": \"Conditional knockout mice (forebrain GABAergic-specific and glutamatergic-specific CB1 deletion), behavioral testing, immunohistochemistry, cytokine measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific genetic loss-of-function with multiple orthogonal readouts establishing CB1 role on GABAergic neurons specifically\",\n      \"pmids\": [\"21690345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The CB1 receptor population on glutamatergic (corticostriatal) terminals, but not on GABAergic neurons, is the essential mediator of neuroprotective activity of (endo)cannabinoids in excitotoxic and Huntington disease models.\",\n      \"method\": \"Conditional knockout mice (glutamatergic-specific and GABAergic-specific CB1 deletion), quinolinic acid excitotoxicity, DREADD pharmacogenetics, R6/2 Huntington mouse model, histopathology\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditional knockouts and disease models with clear pathway placement of specific CB1 receptor populations\",\n      \"pmids\": [\"24843137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB1 receptor activation promotes neuronal differentiation and maturation of neural stem cells via long-term inhibition of the ERK1/2 pathway; this is associated with increased expression of neuronal differentiation genes and decreased stemness genes.\",\n      \"method\": \"NSC differentiation assays, CB1-specific agonist/antagonist (ACEA, CB1 antagonist), ERK1/2 pharmacological inhibition, morphometric analysis, gene array profiling, Western blot, real-time PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in single lab with specific CB1 receptor involvement confirmed by receptor-selective compounds\",\n      \"pmids\": [\"23372698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Genetic or pharmacological inactivation of CB1 (but not CB2) induces preterm birth in mice; CB1 deficiency alters progesterone/estrogen ratios and causes aberrant corticotrophin-releasing hormone and corticosterone activities, which are mechanistically linked to the preterm birth phenotype as CRH antagonist treatment restores normal parturition timing.\",\n      \"method\": \"Cnr1 and Cnr2 knockout mice, pharmacological CB1/CB2 inactivation, radioimmunoassay of hormones, CRH antagonist rescue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with hormonal mechanism identified and pharmacological rescue demonstrating pathway epistasis\",\n      \"pmids\": [\"18833324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CB1 receptors in hippocampal GABAergic neurons regulate GABA release: conditional knockout of CB1 from GABAergic neurons increases frequency and accelerates kinetics of spontaneous IPSCs in CA1 pyramidal neurons and impairs acquisition of spatial memory and novel object recognition.\",\n      \"method\": \"Patch clamp and field potential recordings, conditional GABAergic-specific CB1 knockout mice, behavioral testing\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type specific genetic loss-of-function with electrophysiological and behavioral readouts\",\n      \"pmids\": [\"26739712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor signaling via ERK, Akt, FAK, JNK, Rho, and MMP-2 pathways is required for bFGF-induced endothelial proliferation, migration, and capillary tube formation; CB1 inactivation (siRNA or antagonist) inhibits angiogenesis in vitro and in vivo.\",\n      \"method\": \"siRNA knockdown, pharmacological CB1 antagonism, endothelial proliferation/migration/tube formation assays, rabbit corneal neovascularization assay, mouse oxygen-induced retinopathy model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent CB1 inactivation strategies with multiple in vitro and in vivo readouts\",\n      \"pmids\": [\"21460248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cannabidiol-induced melanogenesis in human epidermal melanocytes is mediated by CB1 receptor (not CB2), acting through phosphorylation of p38 MAPK and p42/44 MAPK to upregulate MITF, independent of cAMP-PKA signaling.\",\n      \"method\": \"CB1/CB2 selective antagonists, Western blot, RT-PCR, melanin content and tyrosinase activity assays, MAPK inhibitors\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — receptor-specific antagonists and kinase inhibitors in primary cells with multiple readouts; single lab\",\n      \"pmids\": [\"28601556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CB1 receptor forms heteromers with Smoothened (Smo), detected by proximity ligation assay; CB1 activation inhibits Shh signaling through allosteric CB1-Smo interactions, and CB1 antagonism attenuates cannabinoid-induced developmental birth defects.\",\n      \"method\": \"Proximity ligation assay (CB1-Smo heteromers), Shh signaling reporter assays, mouse and zebrafish embryo models, CB1 antagonist rescue experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — novel heteromer identified by proximity ligation with functional pharmacological rescue in two model organisms; single lab\",\n      \"pmids\": [\"31690747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB1 receptor activation by cannabinoid receptor agonist WIN55,212 inhibits trigeminovascular neuronal responses to A- and C-fiber dural afferents; this effect is blocked by CB1 antagonist SR141716 but not CB2 antagonist AM630, establishing CB1 as the mediator.\",\n      \"method\": \"Extracellular electrophysiology in rat trigeminocervical complex, selective CB1 and CB2 antagonists\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo electrophysiology with receptor-selective pharmacological dissection\",\n      \"pmids\": [\"17018694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Constitutive activity of the CB1 receptor maintains TRPV1 in a sensitized state responsive to noxious chemical stimuli; CB1 inverse agonists inhibit capsaicin-induced calcium influx and flinching responses, and CB1 knockout mice show significantly decreased capsaicin-evoked CGRP release and action potentials.\",\n      \"method\": \"CB1 knockout mice, calcium influx assay in F-11 cells, spinal cord CGRP release assay, skin-nerve preparation electrophysiology, CB1 inverse agonists\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and pharmacological loss-of-function with multiple complementary mechanistic readouts establishing CB1-TRPV1 interaction\",\n      \"pmids\": [\"18987195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CB1 receptor regulates intestinal permeability via endocannabinoid (AEA and 2-AG) signaling; CB1 knockdown reduces permeability response to inflammation; 2-AG levels increase in response to inflammation and hypoxia in Caco-2 cells.\",\n      \"method\": \"CB1 siRNA knockdown (Caco-2 cells), transepithelial electrical resistance, FAAH/MAGL inhibitors, CB1 antagonist, mass spectrometry for endocannabinoid measurement\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown and pharmacological tools with quantitative permeability and endocannabinoid measurements\",\n      \"pmids\": [\"28404744\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR1/CB1 is a Gi/o-coupled GPCR that inhibits adenylyl cyclase, suppresses voltage-gated Ca2+ channels, activates inwardly rectifying K+ channels, and activates MAPK cascades (ERK1/2, p38, JNK); agonist binding triggers GRK3-mediated phosphorylation of S426/S430 in the C-terminal tail, beta-arrestin 2 recruitment and receptor desensitization, followed by clathrin-mediated internalization requiring the distal C-terminus; structural studies reveal that orthosteric agonists drive rearrangement of a TM2-centered toggle switch to activate G protein, while both positive and negative allosteric modulators bind an extrahelical TM2-TM3-TM4 site to facilitate or impede this rearrangement; CB1 also forms functional heteromers with CB2, GPR55, beta2-adrenoceptor, and Smoothened with altered pharmacological properties; at synapses CB1 on glutamatergic terminals mediates endocannabinoid retrograde suppression of neurotransmitter release and neuroprotection, while CB1 on GABAergic interneurons regulates inhibitory tone and protects against neuroinflammation; a functional pool within mitochondrial membranes (mtCB1) modulates ATP production and synaptic transmission.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"CB1 (CNR1) was cloned from rat brain cDNA and identified as a G protein-coupled receptor with seven transmembrane helices that inhibits adenylate cyclase activity in a dose-dependent, stereoselective, and pertussis toxin-sensitive manner, establishing it as the neuronal receptor mediating cannabis effects.\",\n      \"method\": \"cDNA cloning, functional expression in cell lines, adenylate cyclase inhibition assay, radioligand binding\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with functional reconstitution; foundational paper with >3900 citations\",\n      \"pmids\": [\"2165569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Human CB1 receptor cDNA was cloned from brain and testis; the protein shares 97.3% identity with rat CB1, and stably transfected CHO-K1 cells show dose-dependent, stereoselective inhibition of forskolin-induced cAMP accumulation upon cannabinoid agonist treatment, confirming functional coupling to Gi.\",\n      \"method\": \"cDNA cloning from human brain cDNA library, stable transfection in CHO-K1 cells, cAMP assay, radioligand binding ([3H]CP55940)\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in heterologous cells with functional readout; >535 citations\",\n      \"pmids\": [\"1718258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Alternative splicing of the human CNR1 gene produces a shorter isoform (CB1A) lacking 61 N-terminal amino acids (with a distinct 28 amino acid N-terminus), present at up to 20% of CB1 levels in brain and peripheral tissues; a similar splice variant exists in rat.\",\n      \"method\": \"RT-PCR of human and rat cDNA libraries, cDNA sequencing, Northern blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular characterization of splice variant with sequence verification; >247 citations\",\n      \"pmids\": [\"7876112\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"CB1 receptor activation by the cannabinoid agonist CP-55940 in human astrocytoma cells (U373 MG) induces expression of the immediate-early gene krox-24 (egr-1/NGFI-A) via a pertussis toxin-sensitive G-protein pathway independent of cAMP metabolism; this was confirmed in CHO cells transfected with human CB1.\",\n      \"method\": \"Western blot, EMSA, pertussis toxin treatment, CHO cell transfection with human CB1, CB1 antagonist SR141716A blockade\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (Western blot, EMSA, pharmacological controls) with heterologous expression confirmation\",\n      \"pmids\": [\"7775459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CB1 receptors undergo rapid agonist-induced internalization via clathrin-coated pits; internalization does not require activated Gαi, Gαo, or Gαs subunits; a region of the extreme C-terminus (last 14 residues) is necessary for internalization. Recycling of internalized CB1 to the cell surface requires endosomal acidification and dephosphorylation.\",\n      \"method\": \"Receptor internalization assays, hypertonic sucrose blockade, C-terminal truncation mutants, pharmacological tools in heterologous expression system\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis of internalization domain with multiple mechanistic controls; >243 citations\",\n      \"pmids\": [\"10428044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GRK3 and β-arrestin 2 mediate homologous CB1 receptor desensitization in Xenopus oocytes; phosphorylation of S426 or S430 in the C-terminal tail is required for desensitization but not for internalization, establishing distinct molecular domains for these two regulatory processes.\",\n      \"method\": \"Xenopus oocyte electrophysiology (Kir3 current), co-expression of GRK3/β-arrestin 2, site-directed mutagenesis of S426A and S430A, CB1 C-terminal truncation mutants\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis defining specific phosphorylation sites; >209 citations\",\n      \"pmids\": [\"10234009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CB1 receptor activation mediates cell migration (chemotaxis and chemokinesis) in HEK293 cells via pertussis toxin-sensitive Gi proteins; the migratory response requires MAPK activation but not adenylate cyclase inhibition.\",\n      \"method\": \"Boyden chamber migration assay with stable CB1-expressing HEK293 cells, pertussis toxin treatment, MEK inhibitor PD098059, CB1 antagonist SR141716A, checkerboard analysis\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — heterologous expression with pharmacological controls and multiple mechanistic tests\",\n      \"pmids\": [\"10871313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CB1 receptors are localized in lipid raft microdomains in C6 glioma cells; disruption of lipid rafts with methyl-β-cyclodextrin (MCD) approximately doubles CB1 binding efficiency and amplifies CB1-dependent signaling via adenylate cyclase and p42/p44 MAPK; CB1 activation within rafts underlies anandamide-induced apoptosis and cytochrome c release.\",\n      \"method\": \"Membrane fractionation, [35S]GTPγS binding assay, adenylate cyclase assay, MAPK phosphorylation, apoptosis assay (cytochrome c release), methyl-β-cyclodextrin disruption of rafts\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking lipid raft localization to CB1 functional signaling\",\n      \"pmids\": [\"15657045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CB1 receptor activation by WIN55,212-2 increases intracellular calcium via coupling to Gq/11 proteins and phospholipase C, releasing calcium from IP3- and ryanodine receptor-sensitive intracellular stores; this Gq-mediated calcium mobilization is WIN-specific and not triggered by other cannabinoid agonist classes (THC, CP55940, anandamide, HU-210).\",\n      \"method\": \"Calcium photometry in CB1-expressing HEK293 cells and hippocampal neurons, pertussis toxin pretreatment, dominant-negative Gαq expression, PLC inhibitors, IP3 receptor and ryanodine receptor inhibitors\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with dominant-negative proteins, pharmacological dissection, and multiple inhibitors confirming the signaling pathway\",\n      \"pmids\": [\"16365309\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Human sperm express CB1 (but not CB2) receptor, localized to the sperm head and midpiece; CB1 activation by anandamide reduces sperm motility, inhibits capacitation-induced acrosome reaction, causes rapid plasma membrane hyperpolarization, and reduces mitochondrial activity, all reversed by CB1 antagonist SR141716A.\",\n      \"method\": \"RT-PCR, Western blot, anandamide treatment with CB1 antagonist, rhodamine 123 fluorescence (mitochondrial activity), intracellular calcium measurement, K+ channel blockade\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional readouts with receptor-specific pharmacological controls in native human tissue\",\n      \"pmids\": [\"15562018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Striatal CB1 and adenosine A2A receptors form heteromeric complexes demonstrated in co-transfected HEK-293T cells and rat striatum; CB1 receptor signaling in a neuroblastoma cell line is completely dependent on A2A receptor activation, and intrastriatal A2A receptor blockade counteracts cannabinoid-induced motor depression.\",\n      \"method\": \"Co-immunoprecipitation, co-localization immunofluorescence in striatum, bimolecular fluorescence complementation, cAMP assays, in vivo intrastriatal pharmacology\",\n      \"journal\": \"Neuropsychopharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal biochemical and functional evidence for heteromer formation with in vivo behavioral validation\",\n      \"pmids\": [\"17356572\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB1 receptors promote oxidative stress and cardiomyocyte cell death via reactive oxygen species generation and activation of p38 and JNK MAPK pathways; CB1 knockout mice show markedly attenuated doxorubicin-induced cardiac dysfunction and cell death, and CB1 agonists (AEA, HU210) enhance doxorubicin-induced MAPK activation and cell death in human primary cardiomyocytes.\",\n      \"method\": \"CB1 knockout mice, pressure-volume conductance system (cardiac function), MAPK activation (Western blot), flow cytometry (ROS, cell death), co-administration of CB1 agonists/antagonists and MAPK inhibitors in human cardiomyocytes\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout plus pharmacological dissection in both mouse models and primary human cells\",\n      \"pmids\": [\"19942623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CB1 and β2-adrenoceptors form physical heteromers (demonstrated by BRET) in HEK293H cells; co-expression reduces CB1 constitutive activity, increases CB1 cell surface expression, and alters signaling: enhancing Gαi-dependent ERK phosphorylation but decreasing non-Gαi-mediated CREB phosphorylation; similar functional interactions occur in primary human trabecular meshwork cells endogenously co-expressing both receptors.\",\n      \"method\": \"BRET, receptor trafficking assays, ERK phosphorylation, CREB phosphorylation, CB1 inverse agonist AM251 vs. neutral antagonist O-2050 pharmacology\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — BRET heteromer detection plus multiple functional readouts validated in endogenous cell system\",\n      \"pmids\": [\"20590567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor activation by AEA (but not 2-AG unless MAGL is inhibited) suppresses RhoA GTPase activity in prostate carcinoma cells, causing loss of actin/myosin microfilaments and reduced cell migration; CB1 antagonism (AM251) increases RhoA activity and promotes migration, indicating constitutive endocannabinoid-CB1 tone chronically represses RhoA.\",\n      \"method\": \"RhoA/Rac1/Cdc42 activity pull-down assays, CB1 agonist/antagonist treatment (WIN55212, AM251), MAGL inhibitor JZL184, actin/myosin staining, Boyden chamber migration assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical GTPase assays with pharmacological dissection linked to defined cellular phenotype\",\n      \"pmids\": [\"22087025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB1 and CB2 cannabinoid receptors form heteromers in transfected neuronal cells and in rat brain regions (pineal gland, nucleus accumbens, globus pallidus); within these heteromers, co-activation of CB1 and CB2 produces negative cross-talk in Akt phosphorylation and neurite outgrowth, and CB1 antagonists can block CB2 agonist effects and vice versa (bidirectional cross-antagonism).\",\n      \"method\": \"BRET, FRET, co-immunoprecipitation, neurite outgrowth assay, Akt phosphorylation, rat brain tissue biochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple biophysical methods demonstrating heteromer formation plus functional readouts; replicated in native tissue\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"GPR55 and CB1 receptors form heteromers in HEK293 cells; co-expression of CB1 specifically inhibits GPR55-mediated transcription factor activation (NFAT, SRE) and ERK1/2 phosphorylation, while GPR55 presence enhances CB1-mediated ERK1/2 and NFAT activation; internalization of both receptors is unaffected by heteromerization.\",\n      \"method\": \"Co-immunoprecipitation, BRET, transcription factor activation assays (NFAT, SRE luciferase), ERK1/2 phosphorylation, receptor internalization assays in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — BRET plus multiple functional signaling readouts demonstrating heteromer-specific pharmacology\",\n      \"pmids\": [\"23161546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of human CB1 in complex with the antagonist AM6538 determined at 2.8 Å resolution, revealing the orthosteric binding pocket architecture and key residues for antagonist/agonist interactions; combined with molecular modeling, the structure explains binding modes of THC and synthetic cannabinoids.\",\n      \"method\": \"X-ray crystallography (2.8 Å), molecular modeling, functional studies\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with functional validation; >422 citations\",\n      \"pmids\": [\"27768894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of CB1 bound to the negative allosteric modulator (NAM) ORG27569 and agonist CP55940 reveals the NAM binds to an extrahelical site within the inner membrane leaflet overlapping a conserved cholesterol-binding site in class A GPCRs; the ternary complex captures an intermediate state where aromatic residues at the base of the agonist-binding pocket adopt an inactive conformation despite orthosteric pocket contraction.\",\n      \"method\": \"X-ray crystallography (ternary complex structure), mutagenesis, radioligand binding assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution structure with functional validation; >147 citations\",\n      \"pmids\": [\"31659318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cryo-EM and crystal structures of CB1 bound to positive allosteric modulator (PAM) ZCZ011 show it binds to an extrahelical TM2-TM3-TM4 site; molecular dynamics simulations and mutagenesis reveal TM2 rearrangement is critical for allosteric signal propagation — PAM ZCZ011 promotes TM2 rearrangement favoring receptor activation, while NAM ORG27569 (binding the same site) impedes TM2 rearrangement.\",\n      \"method\": \"X-ray crystallography, cryo-EM, molecular dynamics simulations, mutagenesis, functional assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple structural methods plus MD simulations and mutagenesis revealing the allosteric mechanism\",\n      \"pmids\": [\"35637350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of CB1 in active signaling complex with the endocannabinoid analog AMG315 (anandamide analog) reveals eCB-specific binding pocket features; ligand interactions with 'toggle switch' residues F200(3.36) and W356(6.48) and with TM2 drive intracellular TM2 rearrangements that determine G protein activation efficacy — these TM2 changes are unique to CB1 and are exploited by CB1-specific allosteric modulators.\",\n      \"method\": \"Cryo-EM, docking, molecular dynamics simulations, mutagenesis, Gα signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM active-state structure with MD and mutagenesis mechanistic validation\",\n      \"pmids\": [\"37160876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor is required for normal axonal growth and fasciculation during embryonic development; pharmacological inhibition of CB1 in chick embryos and morpholino-mediated knockdown in zebrafish both caused defects in axon pathfinding and fasciculation, coincident with expression of enzymes for 2-AG synthesis in overlapping patterns.\",\n      \"method\": \"CB1 pharmacological inhibition in chick embryo, morpholino knockdown in zebrafish, immunohistochemistry, in situ hybridization\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockdown plus pharmacological inhibition in two vertebrate models with defined developmental phenotype\",\n      \"pmids\": [\"18378465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of CB1 (Cnr1−/−) induces preterm birth in mice; CB1 deficiency alters progesterone/estrogen ratios prior to parturition and causes aberrant corticotropin-releasing hormone (CRH) and corticosterone secretion; CRH antagonist rescues normal parturition timing in Cnr1−/− mice, and excess corticosterone induces preterm birth in wild-type mice, placing CB1 upstream of the CRH-driven endocrine axis in labor regulation.\",\n      \"method\": \"Cnr1 knockout mice (genetic), radioimmunoassay of steroid hormones, CRH antagonist treatment, corticosterone administration in WT mice, Ptgs1/Cnr1 double-knockout epistasis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with double KO and pharmacological rescue defining CB1's position in the parturition endocrine axis\",\n      \"pmids\": [\"18833324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB1 receptor antagonism (SR141716A) in mice and Cnr1−/− mice reduces liver fibrosis progression in three chronic liver injury models; CB1 activation by endocannabinoids promotes fibrogenesis by increasing hepatic TGF-β1 and by promoting survival and proliferation of hepatic myofibroblasts; CB1 is highly induced in human cirrhotic liver and in liver fibrogenic cells.\",\n      \"method\": \"Cnr1 knockout mice, CB1 antagonist SR141716A in three chronic liver injury models, TGF-β1 measurement, fibrogenic cell apoptosis/proliferation assays, human cirrhotic tissue immunohistochemistry\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout replicated by pharmacological antagonism in multiple disease models; >430 citations\",\n      \"pmids\": [\"16715087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Genetic and siRNA-mediated inactivation of CB1 receptors inhibits bFGF-induced endothelial proliferation, migration, and tube formation through prosurvival/migratory pathways involving ERK, Akt, FAK, JNK, Rho, and MMP-2; CB1 blockade inhibits neovascular growth in rabbit cornea and reduces pathologic neovascularization in mouse oxygen-induced retinopathy in vivo.\",\n      \"method\": \"siRNA knockdown of CB1, CB1 antagonist pharmacology, endothelial proliferation/migration/tube formation assays, ERK/Akt/FAK/JNK/Rho/MMP-2 pathway analysis, rabbit cornea neovascularization assay, mouse oxygen-induced retinopathy model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic silencing plus pharmacological antagonism with defined signaling pathway readouts and in vivo validation\",\n      \"pmids\": [\"21460248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor activity on hippocampal GABAergic (but not glutamatergic) neurons protects against age-dependent cognitive decline, pyramidal cell degeneration, and neuroinflammation; conditional deletion of CB1 from forebrain GABAergic neurons replicates the hippocampal neuron loss and elevated IL-6/microglial activation seen in complete Cnr1−/− mice.\",\n      \"method\": \"Conditional Cnr1 knockout (GABAergic vs. glutamatergic specific), Morris water maze, neuronal counting, IL-6 ELISA, immunohistochemistry for astrocytes and microglia\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional knockout with defined molecular and cellular phenotype\",\n      \"pmids\": [\"21690345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CB1 receptors on glutamatergic (but not GABAergic) corticostriatal terminals are the essential population mediating neuroprotective effects of cannabinoids; conditional deletion of CB1 from glutamatergic neurons removes neuroprotection against quinolinic acid excitotoxicity and in the R6/2 Huntington disease model, while GABAergic CB1 deletion does not.\",\n      \"method\": \"Conditional Cnr1 knockout (glutamatergic vs. GABAergic), quinolinic acid excitotoxicity model, R6/2 Huntington mouse model, DREADD pharmacogenetic remote manipulation of corticostriatal projections\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional knockout with two disease models and orthogonal chemogenetic approach\",\n      \"pmids\": [\"24843137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB1 activation in neural stem cells (NSCs) via anandamide or ACEA (CB1-specific agonist but not CB2-specific agonist) enhances neuronal differentiation and maturation via long-term inhibition of the ERK1/2 pathway; pharmacological ERK1/2 inhibition mimics CB1-driven neuronal differentiation; CB1 activation also upregulates neuronal differentiation genes and suppresses stemness genes.\",\n      \"method\": \"NSC differentiation assays (ALP activity, morphometric neurite analysis), ERK1/2 phosphorylation assay, selective CB1/CB2 agonists and antagonists, gene array profiling, RT-PCR and Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective receptor pharmacology with multiple functional readouts and gene expression profiling\",\n      \"pmids\": [\"23372698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CB1 receptor activation in human bone marrow MSCs enhances osteogenic differentiation by increasing mitochondrial energy metabolism (oxygen consumption rate, mitochondrial membrane potential) and Nrf1/Nrf2 expression; CB1 activates JNK and p38 MAPK pathways while inhibiting Erk1/2, and CB1 can rescue impaired osteogenic differentiation caused by mitochondrial electron transport chain inhibition.\",\n      \"method\": \"Alkaline phosphatase assay, alizarin red staining, Seahorse Mito Stress Test (OCR), JC-10 MMP assay, Western blot for signaling kinases, rotenone and CoQ10 pharmacology, CB1 siRNA knockdown\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic readouts in human primary cells with pharmacological and genetic perturbation\",\n      \"pmids\": [\"35063024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cannabinoids (Δ9-THC, HU-210, CP55940) inhibit Sonic Hedgehog signaling by blocking Smoothened (Smo) function; proximity ligation assays identified CB1-Smo heteromers in vivo, suggesting allosteric CB1-Smo interactions underlie CB-induced craniofacial and brain developmental defects in mice and zebrafish; a CB1 antagonist attenuated cannabinoid-induced birth defects.\",\n      \"method\": \"Mouse and zebrafish developmental models, Shh pathway reporter assays, proximity ligation assay (CB1-Smo heteromers), CB1 antagonist rescue experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — proximity ligation evidence for novel CB1-Smo heteromers plus in vivo genetic/pharmacological rescue; single lab\",\n      \"pmids\": [\"31690747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cannabidiol-induced melanogenesis in human epidermal melanocytes is mediated by CB1 receptor (not CB2), acting through phosphorylation of p38 MAPK and p42/44 MAPK to upregulate MITF gene expression and downstream melanogenic enzymes (tyrosinase, TRP1, TRP2), independently of cAMP-PKA signaling.\",\n      \"method\": \"Melanin content assay, tyrosinase activity assay, CB1/CB2 selective antagonists, kinase inhibitors, RT-PCR and Western blot in human melanocytes\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — selective receptor antagonism with multiple signaling readouts in human primary cells\",\n      \"pmids\": [\"28601556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor constitutive activity maintains TRPV1 channels in a sensitized state responsive to capsaicin; CB1 knockout mice show markedly reduced capsaicin-evoked CGRP release from spinal cord and reduced action potential firing in isolated skin-nerve preparations, without differences in TRPV1 expression; CB1 inverse agonists inhibit capsaicin-induced calcium influx and nociceptive flinching.\",\n      \"method\": \"CB1 knockout mice, capsaicin-evoked CGRP release from spinal cord tissue, skin-nerve electrophysiology, calcium influx assay in F-11 cells, nociceptive behavioral tests, galanin/bradykinin sensitization rescue\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with multiple mechanistic endpoints (neurochemical, electrophysiological, and behavioral) establishing constitutive CB1 activity as a prerequisite for TRPV1 sensitization\",\n      \"pmids\": [\"18987195\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR1/CB1 is a seven-transmembrane Gi/o-coupled GPCR that inhibits adenylate cyclase, activates MAPK cascades, regulates voltage-gated Ca2+ and inwardly-rectifying K+ channels, and can also couple to Gq/11 to mobilize intracellular calcium; desensitization is mediated by GRK3 phosphorylation of S426/S430 and β-arrestin 2 recruitment, while distinct C-terminal residues govern clathrin-dependent internalization and recycling; structural studies have defined the orthosteric binding pocket and two extrahelical allosteric sites at the TM2-TM3-TM4 surface whose occupancy controls TM2 rearrangements that bias G protein coupling efficacy; CB1 forms functional heteromers with CB2, A2A, β2-adrenergic, GPR55, and Smoothened receptors that alter signaling properties; in vivo, cell-type-restricted CB1 populations (glutamatergic vs. GABAergic terminals) serve distinct physiological roles including neuroprotection, fear extinction, axonal development, parturition, liver fibrosis, angiogenesis, osteogenesis, sperm function, and intestinal permeability.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CNR1 (CB1) is a Gi/o-coupled G protein-coupled receptor that serves as the principal neuronal mediator of endocannabinoid signaling, regulating synaptic transmission, neuroprotection, pain processing, and peripheral functions including gut permeability and parturition timing. CB1 inhibits adenylyl cyclase, suppresses voltage-gated Ca²⁺ channels, activates inwardly rectifying K⁺ channels, and engages MAPK cascades (ERK1/2, p38, JNK) to control cell migration, angiogenesis, and neuronal differentiation [PMID:9336020, PMID:10871313, PMID:21460248, PMID:23372698]. Agonist-induced desensitization requires GRK3-mediated phosphorylation of S426/S430 and β-arrestin 2 recruitment, while clathrin-dependent internalization depends on the distal C-terminus independently of these phosphorylation sites [PMID:10234009, PMID:10428044]. Structural studies reveal that orthosteric agonists activate G protein through a TM2-centered toggle switch involving F200(3.36) and W356(6.48), and both positive and negative allosteric modulators bind an overlapping extrahelical TM2-TM3-TM4 site to promote or impede this rearrangement [PMID:31659318, PMID:35637350, PMID:37160876].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that CB1 couples to Gi/o to activate downstream gene expression programs resolved how cannabinoid receptor engagement translates into transcriptional responses beyond cAMP inhibition.\",\n      \"evidence\": \"Western blot, EMSA, pertussis toxin blockade, and CB1-selective antagonist SR141716A in CB1-transfected CHO and astrocytoma cells\",\n      \"pmids\": [\"7775459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcription factor cascade from Gi/o to krox-24 not fully delineated\", \"Relevance of this pathway in neurons in vivo not established\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Comprehensive pharmacological characterization established CB1 as a Gi/o-coupled GPCR that inhibits adenylyl cyclase and modulates Ca²⁺ and K⁺ channels, providing the canonical signaling framework for all subsequent mechanistic work.\",\n      \"evidence\": \"Replicated pharmacological binding and effector assays across multiple laboratories\",\n      \"pmids\": [\"9336020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of specific Gα subunit isoforms mediating each effector arm not resolved\", \"Tissue-specific signaling bias not yet explored\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defining the molecular determinants of CB1 desensitization versus internalization showed these are mechanistically separable: GRK3/β-arrestin 2-dependent desensitization requires S426/S430 phosphorylation, while clathrin-mediated internalization requires the distal C-terminal 14 residues independently.\",\n      \"evidence\": \"Xenopus oocyte Kir3 electrophysiology with GRK3/β-arrestin 2 co-expression, C-terminal truncation/point mutants; cell-based internalization assays with hypertonic sucrose and C-terminal deletions\",\n      \"pmids\": [\"10234009\", \"10428044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Additional phosphorylation sites contributing to desensitization not mapped\", \"Post-internalization recycling vs. degradation pathway choice not mechanistically resolved\", \"Whether β-arrestin also contributes to signaling (not just desensitization) was not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that CB1 drives cell migration via Gi-dependent MAPK activation, independent of adenylyl cyclase, revealed a bifurcation in CB1 effector coupling with distinct functional outputs.\",\n      \"evidence\": \"Boyden chamber chemotaxis in CB1-expressing HEK293 cells with pertussis toxin, MEK inhibitor PD098059, and CB1 antagonist\",\n      \"pmids\": [\"10871313\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Small GTPase intermediaries linking Gi to ERK not identified\", \"In vivo relevance of CB1-driven migration not established\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic proof using two independent CB1 knockout lines confirmed that CB1 on glutamatergic terminals is the receptor mediating cannabinoid-induced suppression of hippocampal synaptic transmission, anchoring CB1 as the retrograde endocannabinoid receptor at excitatory synapses.\",\n      \"evidence\": \"Extracellular field recordings in hippocampal slices from two independent CB1 knockout mouse lines\",\n      \"pmids\": [\"16527424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Contribution of presynaptic versus postsynaptic CB1 pools not dissected\", \"Endocannabinoid identity (2-AG vs AEA) mediating this effect not determined here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"CB1 was found to regulate functions beyond classical neurotransmission: axonal growth and fasciculation during development, parturition timing via CRH/corticosterone axis control, and constitutive maintenance of TRPV1 sensitization in pain circuits.\",\n      \"evidence\": \"Zebrafish morpholino knockdown and pharmacological inhibition for axon guidance; Cnr1 knockout mice with CRH antagonist rescue for parturition; CB1 knockout mice with calcium influx, CGRP release, and skin-nerve electrophysiology for TRPV1\",\n      \"pmids\": [\"18378465\", \"18833324\", \"18987195\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking CB1 constitutive activity to TRPV1 sensitization at the molecular level unknown\", \"Whether CB1 axon guidance role is cell-autonomous not determined\", \"How CB1 regulates CRH transcription or secretion not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Cell-type-specific conditional knockouts revealed that CB1 on GABAergic interneurons protects against age-dependent neuroinflammation and cognitive decline, while CB1 on glutamatergic terminals mediates neuroprotection against excitotoxicity, establishing that the same receptor serves distinct protective functions depending on its cellular context.\",\n      \"evidence\": \"Forebrain GABAergic- and glutamatergic-specific CB1 conditional knockout mice with behavioral, histological, cytokine, and excitotoxicity readouts; DREADD validation; R6/2 Huntington model\",\n      \"pmids\": [\"21690345\", \"24843137\", \"26739712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling cascades specific to each cell type not identified\", \"Whether mtCB1 contributes to neuroprotection not tested in conditional knockouts\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"CB1 was shown to be required for bFGF-induced angiogenesis, acting through ERK, Akt, FAK, JNK, Rho, and MMP-2 signaling, expanding CB1 function to vascular biology.\",\n      \"evidence\": \"siRNA knockdown and pharmacological antagonism in endothelial cells; corneal neovascularization and oxygen-induced retinopathy in vivo models\",\n      \"pmids\": [\"21460248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CB1 acts directly on endothelial cells or via paracrine endocannabinoid production not fully resolved\", \"Mechanism of CB1-MMP2 coupling unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of functional CB1–CB2 and CB1–GPR55 heteromers with bidirectional cross-antagonism and altered signaling outputs established that CB1 pharmacology is context-dependent and shaped by heteromerization state.\",\n      \"evidence\": \"BRET/FRET, co-IP in transfected cells and rat brain tissue (CB1-CB2); co-IP and reporter assays in HEK293 (CB1-GPR55)\",\n      \"pmids\": [\"22532560\", \"23161546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo stoichiometry and prevalence of heteromers in specific brain regions unknown\", \"GPR55 heteromer data limited to heterologous system\", \"Structural basis of cross-antagonism not determined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A mitochondrial pool of CB1 (mtCB1) was recognized to directly modulate ATP production and thereby influence synaptic transmission, identifying a non-canonical site of action for CB1.\",\n      \"evidence\": \"Subcellular fractionation, mitochondrial functional assays, electrophysiology, behavioral testing (cited in review)\",\n      \"pmids\": [\"29058339\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of CB1 targeting to mitochondrial membranes unknown\", \"Which Gα subunit couples to mtCB1 not resolved\", \"Proportion of total CB1 in mitochondria versus plasma membrane not quantified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structures of CB1 with negative allosteric modulator ORG27569 and agonist CP55940 revealed the NAM binding site at an extrahelical TM2-TM3-TM4 locus and captured an intermediate receptor conformation, providing the first structural basis for allosteric modulation of CB1.\",\n      \"evidence\": \"X-ray crystallography with functional validation\",\n      \"pmids\": [\"31659318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the intermediate state transitions to fully inactive or active conformations not captured\", \"No structure with G protein in the allosteric-modulated complex\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Structures with PAM ZCZ011 showed it binds the same extrahelical TM2-TM3-TM4 site as the NAM but promotes rather than impedes TM2 rearrangement, establishing a unified structural framework where positive and negative allosteric modulators act through opposing effects on the same conformational switch.\",\n      \"evidence\": \"X-ray crystallography, cryo-EM, MD simulations, mutagenesis, and functional signaling assays\",\n      \"pmids\": [\"35637350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full ternary complex of PAM+agonist+Gi captured\", \"Whether PAM and NAM can co-bind simultaneously unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Cryo-EM with an endocannabinoid analog identified F200(3.36) and W356(6.48) toggle-switch residues and TM2-ligand contacts as key determinants of G protein activation efficacy, completing the structural picture of how orthosteric ligand binding propagates to the intracellular face.\",\n      \"evidence\": \"Cryo-EM, docking, MD simulations, mutagenesis, signaling assays\",\n      \"pmids\": [\"37160876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of biased agonism (G protein vs β-arrestin) not resolved\", \"Endocannabinoid-bound active-state structure with Gi complex not yet available\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for β-arrestin-biased signaling at CB1, the targeting mechanism and signaling machinery of mitochondrial CB1, the in vivo stoichiometry and functional relevance of CB1 heteromers in defined neural circuits, and how allosteric modulators alter heteromer pharmacology.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No biased agonism structures available\", \"mtCB1 targeting and coupling mechanism unknown\", \"Heteromer structures not determined\", \"Allosteric modulation in heteromer context untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 5, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 3, 6]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0007186\", \"supporting_discovery_ids\": [0, 1, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 4, 5, 6]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [15, 17, 18, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 20]}\n    ],\n    \"complexes\": [\n      \"CB1-CB2 heteromer\",\n      \"CB1-GPR55 heteromer\",\n      \"CB1-β2AR heteromer\",\n      \"CB1-Smoothened heteromer\"\n    ],\n    \"partners\": [\n      \"CNR2\",\n      \"GPR55\",\n      \"ADRB2\",\n      \"SMO\",\n      \"GRK3\",\n      \"ARRB2\",\n      \"TRPV1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CNR1 (CB1) is a Gi/o-coupled seven-transmembrane receptor that serves as the principal neuronal mediator of endocannabinoid signaling, with additional critical roles in peripheral tissues including liver, vasculature, bone, reproductive organs, and skin. CB1 inhibits adenylate cyclase and activates MAPK cascades (ERK1/2, p38, JNK) through pertussis toxin-sensitive G proteins, and can additionally couple to Gq/11 in a ligand-selective manner to mobilize intracellular calcium via PLC and IP3/ryanodine receptor stores [PMID:2165569, PMID:16365309, PMID:10871313]. Desensitization requires GRK3-mediated phosphorylation of C-terminal residues S426/S430 and β-arrestin 2 recruitment, while clathrin-dependent internalization depends on a distinct extreme C-terminal domain [PMID:10234009, PMID:10428044]; structural studies have defined the orthosteric binding pocket and an extrahelical TM2-TM3-TM4 allosteric site where positive and negative modulators control TM2 rearrangements that determine G protein coupling efficacy [PMID:27768894, PMID:31659318, PMID:35637350]. Cell-type-restricted CB1 populations exert distinct physiological functions—CB1 on glutamatergic terminals mediates neuroprotection against excitotoxicity, whereas CB1 on GABAergic neurons protects against age-dependent neurodegeneration and neuroinflammation—and CB1 forms functional heteromers with A2A, β2-adrenergic, CB2, GPR55, and Smoothened receptors that reshape downstream signaling [PMID:24843137, PMID:21690345, PMID:17356572, PMID:20590567, PMID:22532560, PMID:23161546].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Cloning of CB1 from rat brain established it as the first molecularly identified cannabinoid receptor and demonstrated that it is a GPCR that inhibits adenylate cyclase via pertussis toxin-sensitive G proteins, answering the long-standing question of how cannabinoids signal in the CNS.\",\n      \"evidence\": \"cDNA cloning, functional expression in cell lines with adenylate cyclase assays and radioligand binding\",\n      \"pmids\": [\"2165569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural information on the ligand-binding pocket\", \"Downstream signaling beyond cAMP inhibition unknown\", \"Endogenous ligand not yet identified at the time\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of an alternative splice variant (CB1A) and CB1-mediated immediate-early gene induction via a cAMP-independent pathway revealed that CB1 signaling extends beyond adenylate cyclase inhibition, opening the MAPK/transcriptional axis of cannabinoid signaling.\",\n      \"evidence\": \"RT-PCR/Northern blot for splice variants; Western blot and EMSA for krox-24 induction in astrocytoma cells with pertussis toxin sensitivity confirmed in CB1-transfected CHO cells\",\n      \"pmids\": [\"7876112\", \"7775459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequences of CB1A isoform unknown\", \"Specific MAPK cascade components not yet mapped\", \"In vivo relevance of cAMP-independent signaling not established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mutagenesis of the CB1 C-terminal tail resolved the paradox of how desensitization and internalization can be independently regulated: GRK3/β-arrestin 2 act on S426/S430 for desensitization, while a distinct extreme C-terminal domain governs clathrin-dependent internalization and recycling.\",\n      \"evidence\": \"Xenopus oocyte electrophysiology with GRK3/β-arrestin 2 co-expression and S426A/S430A mutagenesis; receptor internalization assays with C-terminal truncation mutants and hypertonic sucrose blockade\",\n      \"pmids\": [\"10234009\", \"10428044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites for internalization not mapped\", \"Endosomal sorting machinery not identified\", \"In vivo desensitization kinetics unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two studies expanded the signaling repertoire of CB1: lipid raft localization was shown to constrain CB1 signaling efficacy and enable raft-dependent apoptosis, while ligand-selective coupling to Gq/11 demonstrated that CB1 can mobilize intracellular calcium via PLC independently of Gi/o.\",\n      \"evidence\": \"Membrane fractionation and raft disruption with functional assays in C6 glioma; calcium photometry with dominant-negative Gαq, PLC/IP3R/RyR inhibitors in HEK293 and hippocampal neurons\",\n      \"pmids\": [\"15657045\", \"16365309\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ligand-selective G protein coupling unknown\", \"Physiological triggers for Gq vs. Gi coupling not defined\", \"Lipid raft dynamics in native neurons not characterized\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstration that CB1 promotes liver fibrosis via TGF-β1 and hepatic myofibroblast survival, with Cnr1 knockout or antagonism reducing fibrosis in three injury models, established CB1 as a major peripheral signaling axis in chronic liver disease.\",\n      \"evidence\": \"Cnr1 knockout mice and pharmacological CB1 antagonism in three chronic liver injury models; TGF-β1 measurement; human cirrhotic tissue immunohistochemistry\",\n      \"pmids\": [\"16715087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CB1-expressing cell type in liver fibrosis pathway not conditionally targeted\", \"Mechanism linking CB1 to TGF-β1 induction not resolved\", \"Relevance to human fibrosis progression not tested prospectively\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Three independent studies established diverse in vivo CB1 functions: constitutive CB1 activity tonically sensitizes TRPV1 nociceptive channels, CB1 is required for normal axonal growth and fasciculation during embryonic development, and CB1 deficiency causes preterm birth by deregulating the CRH-corticosterone endocrine axis.\",\n      \"evidence\": \"CB1 knockout mice with CGRP release and skin-nerve electrophysiology; morpholino knockdown in zebrafish plus chick embryo pharmacology; Cnr1 knockout mice with steroid hormone assays and CRH antagonist rescue\",\n      \"pmids\": [\"18987195\", \"18378465\", \"18833324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism by which constitutive CB1 activity sensitizes TRPV1 not identified\", \"Endocannabinoid ligand identity for axon guidance not defined\", \"Human relevance of CB1-CRH axis in parturition not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery of CB1–β2-adrenoceptor heteromers by BRET showed that receptor heterodimerization remodels CB1 constitutive activity, surface trafficking, and signaling bias, validated in primary human trabecular meshwork cells.\",\n      \"evidence\": \"BRET in HEK293H cells; ERK and CREB phosphorylation assays; confirmation in primary human cells endogenously co-expressing both receptors\",\n      \"pmids\": [\"20590567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structure of the heteromer unknown\", \"In vivo physiological consequences of CB1–β2AR heteromers not tested\", \"Heteromer-selective pharmacology not developed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of CB1–CB2 and CB1–GPR55 heteromers with distinct cross-talk properties (bidirectional cross-antagonism for CB1–CB2; asymmetric ERK/NFAT modulation for CB1–GPR55) demonstrated that heteromerization is a general mechanism diversifying cannabinoid receptor pharmacology.\",\n      \"evidence\": \"BRET, FRET, co-immunoprecipitation, neurite outgrowth and Akt/ERK assays in neuronal cells and rat brain tissue (CB1–CB2); BRET and transcription factor reporters in HEK293 (CB1–GPR55)\",\n      \"pmids\": [\"22532560\", \"23161546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Native tissue stoichiometry and heteromer prevalence not quantified\", \"Downstream effectors unique to heteromers vs. homomers not mapped\", \"Therapeutic targeting of specific heteromers not achieved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Cell-type-specific conditional knockouts resolved a key question: CB1 on glutamatergic terminals mediates neuroprotection against excitotoxicity (including in Huntington models), while CB1 on GABAergic neurons prevents age-related hippocampal neurodegeneration and neuroinflammation—establishing that a single receptor exerts opposing circuit-level effects depending on cell type.\",\n      \"evidence\": \"Conditional Cnr1 knockout from glutamatergic vs. GABAergic neurons; quinolinic acid excitotoxicity and R6/2 Huntington models; Morris water maze; IL-6 and microglia immunohistochemistry\",\n      \"pmids\": [\"24843137\", \"21690345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling cascades in each cell type not compared\", \"Whether circuit-level effects are purely presynaptic not resolved\", \"Translation to human neurodegenerative disease not demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The first crystal structure of CB1 (with antagonist AM6538 at 2.8 Å) revealed the orthosteric binding pocket architecture and key ligand-contact residues, enabling rational interpretation of cannabinoid structure–activity relationships.\",\n      \"evidence\": \"X-ray crystallography at 2.8 Å resolution with molecular modeling and functional validation\",\n      \"pmids\": [\"27768894\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state structure not yet available at this point\", \"Allosteric sites not structurally resolved\", \"Membrane environment effects not captured in crystal\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structure of the CB1–ORG27569–CP55940 ternary complex identified an extrahelical NAM site in the inner membrane leaflet overlapping a cholesterol-binding site, capturing an intermediate conformational state that explained how allosteric modulators decouple agonist binding from receptor activation.\",\n      \"evidence\": \"X-ray crystallography of ternary complex; mutagenesis; radioligand binding assays\",\n      \"pmids\": [\"31659318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamic transitions between intermediate and active states not resolved\", \"In vivo relevance of NAM-stabilized intermediate unknown\", \"Selectivity determinants over CB2 at allosteric site not fully mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Structures of CB1 with PAM ZCZ011 at the same TM2-TM3-TM4 extrahelical site as the NAM, combined with MD simulations, revealed that PAM and NAM oppositely control TM2 rearrangement—the key conformational switch determining G protein coupling efficacy—providing a unified allosteric mechanism.\",\n      \"evidence\": \"X-ray crystallography and cryo-EM; molecular dynamics simulations; mutagenesis; functional assays\",\n      \"pmids\": [\"35637350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TM2 rearrangement controls β-arrestin bias not determined\", \"Allosteric cooperativity with orthosteric agonists quantified only for select ligands\", \"Endogenous allosteric modulators of this site not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Active-state cryo-EM structure with an endocannabinoid analog showed that eCB-specific contacts with toggle-switch residues F200/W356 and TM2 drive the G protein activation-determining TM2 rearrangement unique to CB1, explaining how endocannabinoids exploit a receptor-specific activation mechanism.\",\n      \"evidence\": \"Cryo-EM of active CB1-Gi complex; docking; MD simulations; mutagenesis and Gα signaling assays\",\n      \"pmids\": [\"37160876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full signaling complex including β-arrestin not yet structurally resolved\", \"How distinct endocannabinoids (AEA vs. 2-AG) produce differential TM2 conformations is unclear\", \"Integration of allosteric and orthosteric structural data into predictive pharmacology models incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions include: how CB1 heteromer stoichiometry and tissue-specific assembly determine pharmacological outcomes in vivo; the structural basis for ligand-biased Gi vs. Gq coupling; whether endogenous allosteric modulators of the TM2-TM3-TM4 site exist; and how cell-type-specific CB1 signaling cascades produce opposing circuit-level phenotypes in the CNS.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Heteromer-selective therapeutics not developed\", \"Endogenous allosteric modulators unknown\", \"β-arrestin-biased structural states not captured\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 8, 16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 4, 7, 9]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 3, 6, 8, 11, 13, 26, 29]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 10, 24, 25, 30]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [20, 21, 28]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [9, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ARRB2\",\n      \"GRK3\",\n      \"ADORA2A\",\n      \"ADRB2\",\n      \"CNR2\",\n      \"GPR55\",\n      \"SMO\",\n      \"TRPV1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}